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Abstract 
Chronic myeloid leukemia (CML) is a disease characterized by the expansion of 
granulocytic cells.  The BCR-ABL tyrosine kinase inhibitor imatinib, the frontline 
treatment for Ph+ leukemias, can induce complete hematologic and cytogenetic response 
in most chronic phase CML patients.  Despite the remarkable initial clinic effects, it is 
now recognized that imatinib will unlikely cure patients because a small cell population 
containing leukemic stem cells (LSCs) with self-renewal capacity is insensitive to 
tyrosine kinase inhibitors.   
In Chapter I, I briefly review the BCR-ABL kinase and its related signaling 
pathways. BCR-ABL kinase activates several signaling pathways including MAPK, 
STAT, and JNK/SAPK. BCR-ABL also mediates kinase-independent pathways through 
SRC family kinases. I will also discuss pathways involving β-catenin, hedgehog, FoxO 
and Alox5 are critical to the regulation of self-renewal and differentiation in LSC of 
CML.  
As detailed in Chapter II, I describe our work evaluating the effects of 
omacetaxine, a novel CML drug inducing cell apoptosis by inhibition of protein synthesis, 
on self-renewal and differentiation of LSCs and BCR-ABL-induced CML and acute 
lymphoblastic leukemia (B-ALL) in mice. We found that treatment with omacetaxine 
decreased the number of LSCs and prolonged the survival of mice with CML or B-ALL.  
In chapter III, I describe that Alox5 is an essential gene in the function of LSCs 
and CML development. We show evidence that Alox5 affects differentiation, cell division, 
v 
 
and survival of long-term LSCs. Treatment of CML mice with a 5-LO inhibitor also 
impaired the function of LSCs similarly and prolonged survival.  
In chapter IV, I present evidence of our work showing a further dissection the 
Alox5 pathway by comparing the gene expression profiles of wild type and Alox5-/- LSCs. 
We show that Msr1 deletion causes acceleration of CML development. We also show 
that Msr1 affects CML development by regulating the PI3K-AKT pathway and β-catenin.  
Taken together, these results demonstrate that some pathways including Alox5 
and Msr1 play an important role in regulating the self-renewal and differentiation of LSC. 
More efforts should be put into developing the novel strategies that may effectively target 
LSCs and thus cure CML.   
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CHAPTER I 
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia 
The work described in this chapter has been published  
(Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem 
cells of chronic myeloid leukemia. Leukemia. 2010, 24: 1545-1554.   
Sullivan C, Peng C, Chen Y, Li D, Li S. Targeted therapy of chronic myeloid leukemia. 
Biochem Pharmacol. 2010 80(5):584-91 
Chen Y, Peng C, Li D, Li S. Molecular and cellular bases of chronic myeloid leukemia. 
Protein & Cell. 2010, 1 (2): 124-132.) 
 
1.1 Abstract 
Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive 
(Ph+) chronic myeloid leukemia (CML) is highly effective in controlling but not curing 
the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia 
stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not 
associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. 
Development of curative therapies for CML requires the identification of critical 
molecular pathways responsible for the survival and self-renewal of LSCs. In this 
introduction, we will discuss our current understanding of these critical molecular 
pathways in LSCs and the available therapeutic strategies for targeting these stem cells in 
CML. 
1.2 BCR-ABL tyrosine kinase and domain functions 
The Ph chromosome is a type of chromosomal rearrangement and produces a new gene: 
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BCR-ABL.  BCR is a signaling protein that contains multiple modular domains. BCR-
deficient mice develop normally, and one obvious phenotype is that neutrophils produce 
excessive levels of oxygen metabolites following their activation 1. c-ABL, a non-
receptor tyrosine kinase, is expressed in most tissues. In a cell, it is distributed in both the 
nucleus and cytoplasm of cells, and shuttles between the two compartments. It transduces 
signals from cell-surface receptors for growth factors and adhesion receptors to regulate 
cytoskeleton structure 2,3. The fusion of BCR to ABL during the translocation increases 
the tyrosine-kinase activity of ABL, and brings new regulatory domains/motifs to ABL, 
such as the growth factor receptor-binding protein 2 (GRB2) and SH2-binding sites 4. 
Depending on the precise breakpoints in the translocation and RNA splicing, different 
forms of BCR-ABL protein with different molecular weights can be generated in patients, 
such as P190, P210, and P230 5-7.The importance of some domains/motifs of BCR-ABL 
has been validated in vivo. Mice expressing a form of BCR-ABL with a point mutation in 
the ATP-binding site of ABL, which inactivates its kinase activity, do not develop 
leukemia, even when the fusion protein is expressed in the long-term repopulating 
hematopoietic stem/progenitor cells, indicating that the ABL kinase activity is absolutely 
essential for BCR-ABL leukemogenesis in vivo 8. This result is consistent with the 
finding that the kinase activity of ABL is required for BCR-ABL-mediated transformation 
in cultured cells 9. It also demonstrated that the ABL kinase is an excellent target for 
treating CML. In addition to the ABL kinase domain, there are other important 
domains/motifs in BCR-ABL, such as those that regulate the kinase activity of ABL or 
connect to other downstream signaling pathways (Figure 1). The relative importance of 
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various domains of BCR-ABL in neoplastic transformation has been examined. 1). 
Deletion of the SH3 domain of ABL results in a mutant form of the protein with 
increased tyrosine kinase activity, and expression of this truncated protein can transform 
both fibroblast and haematopoietic cell lines in vitro. 2). The amino-terminal coiled-coil 
(CC) oligomerization domain of BCR is an important activator of ABL kinase activity, 
and also promotes the association of BCR–ABL with ACTIN fibers 10. A mutant form of 
BCR-ABL that lacks the BCR-CC domain (ΔCC-BCR-ABL) failed to induce 
myeloproliferative disorders (MPD) in mice. Reactivation of the kinase activity of ABL 
by mutating its SH3 domain (through deletion or a P1013L point mutation), rescued the 
ability of ΔCC-BCR-ABL to induce a CML-like MPD in mice 11. These results 
demonstrate that the BCR domain is essential for the induction of CML by BCR-ABL in 
mice, mainly owing to its ability to activate the kinase activity of ABL. 3). GRB2-
binding site. GRB2 binds SOS as well as the scaffolding adapter GRB2-associated 
binding protein 2 (GAB2). Formation of this complex depends on BCR phosphorylation 
at tyrosine 177 12, leading to activation of downstream RAS and recruitment of protein 
tyrosine phosphatase (SHP2) and phosphatidylinositol 3-kinase (PI3K) 12,13. Mutation of 
the tyrosine-177 residue of BCR-ABL to phenylalanine (Y177F) largely abolished its 
ability to bind GRB2 without affecting the kinase activity of ABL 12,14. 4). The SH2 
domain of ABL is believed to activate RAS, at least partially, through binding to SHC, 
which, following tyrosine phosphorylation, can recruit GRB2 15. Mutations in the SH2 
domain of ABL reduced the ability of BCR-ABL to induce a CML-like MPD in mice 16. 
The Y1294F point mutation in SH2 domain of BCR-ABL also attenuated leukemogenesis 
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by BCR-ABL 11. Together these structure-function analyses of BCR-ABL have shown that 
the activation of the tyrosine-kinase activity of ABL is necessary but not sufficient to 
induce CML in mice.  
1.3 BCR-ABL kinase-dependent or independent signaling pathways 
The potent, constitutively active non-receptor tyrosine-kinase activities of the BCR-ABL 
oncoproteins are responsible for triggering assorted signaling pathways that promote the 
growth and survival of hematopoietic cells and the induction of cell transformation. 
These pathways include those mediated by Ras, mitogen-activated protein kinase 
(MAPK), c-jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), signal transducers and 
activators of transcription (STAT), phosphoinositide 3- (PI-3) kinase, and c-Myc, among 
others(Figure 1). Not all BCR-ABL-expressing cells are killed using kinase-
inhibiting and CML stem cells are insensitive to kinase inhibition.  Targeted approaches 
to the kinase-independent signaling pathways of BCR-ABL are also important. Several 
have been identiﬁed to play important roles in CML development and speciﬁcally LSC 
survival, including the Wnt/β-catenin, Hedgehog, Alox5, SRC family kinase and FoxO 
pathways (Figure 2)  
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Figure 1. BCR-ABL kinase acitivated signaling pathways. 
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Figure 2. BCR-ABL kinase-dependent or independent signaling pathways. 
 
 
 
 
 
 
 
 
 
 
7 
 
1.4 Chronic myeloid leukemia 
Philadelphia-positive (Ph+) chronic myeloid leukemia is a myeloproliferative disease 
characterized by granulocytosis and splenomegaly. The disease course is triphasic, 
starting with a chronic phase, progressing to an accelerated phase, and ultimately ending 
in a terminal phase called blast crisis. The Ph chromosome occurs in over 90% of CML 
cases, and its presence in the setting of other symptoms is diagnostic of CML. Ten years 
ago, allogeneic bone marrow transplantation (BMT) was the recommended treatment for 
newly diagnosed patients with CML.  Recipients of BMT had a high 5-year survival rate 
with a low chance of relapse 17. The majority of long-term survivors with BMT may be 
regarded as operationally ‘cured’, even if some patients still contain quiescent leukemia 
stem cells (LSCs) 18. The question is whether these patients are really cured, and the 
answer to this question should depend on whether the patients are still in danger of 
relapse. The fact is that CML patients receiving BMT can relapse 17, suggesting that 
LSCs are not eliminated. A real cure may require complete eradication of these stem cells. 
Although BMT is considered a “curative” therapy for CML, the cure is apparently 
“relative” due to the existence of residual LSCs. Another major issue in BMT is age 
restriction and availabilities of donors. Current standard therapy for CML is the BCR-
ABL kinase inhibitors such as imatinib mesylate (Gleevec/Glivec, formerly STI571; 
Novartis) 19. After 5 years of treatment, the rate of complete cytogenetic response among 
patients receiving imatinib was 87%, with an estimated 7% of patients progressing to 
accelerated phase CML or blast crisis 20. Although it effectively prolongs the survival of 
CML patients, imatinib does not show any definite prospect of “cure” 18, as these 
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imatinib-treated patients in complete cytogenetic remission still contain malignant 
hematopoietic progenitor cells21. The patients are likely required to take the drug for the 
rest of their lives22 . Is imatinib curative for CML? The fact that half of imatinib treated 
CML patients who achieved molecular remission and subsequently discontinued the 
treatment remained in molecular remission without imatinib suggests that these patients 
appear to be free of leukemia. However, all these patients who remained in molecular 
remission without imatinib had previously been treated with interferon-γ(IFN-γ) 22, 
raising a question as to whether IFN-γ played a critical role in the induction of molecular 
remission by imatinib. Besides these facts, resistance to imatinib develops 20, and one of 
the major reasons for the resistance is the development of point mutations in the BCR-
ABL kinase domain 23,24. In addition, imatinib does not completely eradicate LSCs 21,25, 
which does not appear to be related to the BCR-ABL kinase domain mutations 26,27. 
This ”natural” resistance of LSCs to imatinib, as well as other kinase inhibitors, suggests 
that BCR-ABL somehow turns on unique molecular pathways in LSCs through both 
kinase-dependent and, more importantly, kinase-independent mechanisms. In this 
introduction, we will focus on the pathways responsible for the inability of BCR-ABL 
kinase inhibitors to eradicate LSCs. 
To circumvent issues related to the drug resistance of LSCs, it is essential to fully 
understand how BCR-ABL signals through both kinase-dependent and -independent 
pathways in LSCs.  It is particularly critical to fully understand the biology of BCR-
ABL-expressing LSCs and to identify key genes that play significant roles in their 
survival and self-renewal. Recently, several DNA microarray assays based on CD34+ 
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cells derived from CML patients or Lin-c-Kit+Sca-1+ cells from CML mouse were 
performed, and different strategies were taken to analysis these DNA profiles28-30, 
providing valuable information for identifying critical molecular pathways in LSCs. 
Recent studies in CML LSCs have been reviewed thoroughly by Goldman and colleagues 
31. Therefore, I will not only summarize recent progress in the delineation of novel 
mechanisms and treatment strategies for LSCs in CML, but also extensively summarize 
our understanding of the biology of LSCs through the identification of target genes for 
the development of potential anti-stem cell therapies using CML mouse model. In doing 
so, we will describe in detail why and how the experiments were done to help to explain 
the challenges and solutions to them in current research on CML LSCs. 
 
1.5 Mouse models of CML 
Three types of mouse models for CML are widely used: the BCR-ABL transgenic 
model, the retroviral bone marrow transduction/transplantation model and the human 
xenograft NOD/SCID mouse model (Figure 3). Of these, the most frequently used CML 
mouse model is the retroviral bone marrow transduction/transplantation model, which 
was initially described in 1990s 32-34. The efficiency of CML induction was later 
improved to 100%8,35,36, which allows the use of the model to study in vivo BCR-ABL 
signaling and disease response to new therapeutic strategies. In this model, donor mice 
were treated with 5-fluorouracil (5-FU). Then, donor bone marrow cells were transduced 
with BCR-ABL retrovirus and transplanted into lethally irradiated syngeneic recipient 
mice 36. Similar to human CML, the induced myeloproliferative disease in mice shows 
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increased number of BCR-ABL-expressing mature granulocytes in peripheral blood, 
splenomegaly and bone marrow invasion of LSCs and progenitor cells26. This CML 
model has become an useful tool for identifying novel genes involved in BCR-ABL 
leukemogenesis and for testing new therapeutic targets in LSCs26,27,37. 
The BCR-ABL transgenic mouse model was first developed in 1990 using P190 
form of BCR-ABL.  These transgenic mice are either moribund with or die of acute 
leukemia (myeloid or lymphoid) 10-58 days after birth 38.  This model was refined to be 
driven by the metallothionein promoter.  In this system, when the P210 isoform of BCR-
ABL was expressed, mice showed excessive proliferation of lymphoblasts shortly after 
birth, resembling acute lymphoblastic leukemia (ALL) 39. Later, BCR-ABL inducible 
transgenic mice using a tet-off system were developed, with these mice developing rapid 
ALL40. Although these transgenic mice indicate that BCR-ABL is the cause for leukemia, 
they did not develop typical CML. Recently, inducible CML was observed when BCR-
ABL transgene was driven by tTA placed under the control of the murine stem cell 
leukemia (SCL) gene 3’ enhancer41. 
The most physiologically-relevant mouse model of CML requires the transfer of 
human CML cells into immunodeficient NOD/SCID recipient mice. In doing so, bone 
marrow or peripheral blood cells from CML patients were purified for CD34+ cells, and 
the cells were cultured in serum-free medium containing a serum substitute, comprised of 
the Flt3-ligand, stem cell factor(SCF), interleukin 3(IL-3), interleukin 6(IL-6) and 
granulocyte-colony stimulating factor 42,43. These CD34+ leukemic cells had an in vitro 
progenitor activity and were capable of engrafting immunodeficient NOD/SCID mice 43.  
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This system had been used to test the inhibitory effects of potential drugs on human CML 
cells 44. 
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Figure 3. Mouse model for studying BCR-ABL leukemia. 
There are three major types of mouse models of CML. a. BCR-ABL transgenic model. 
Inducible expression of BCR-ABL controlled by tTA tet-off system in BCR-ABL 
transgenic mouse. b. Retroviral bone marrow transduction/transplantation model. Bone 
marrow cells from 5-FU treated donor mice are transduced with BCR-ABL retrovirus, 
cultured in the presence of cytokines, and then transplanted into lethally irradiated 
syngeneic recipient mice. c. Human xenograft NOD/SCID mouse model. Bone marrow 
or peripheral blood cells from CML patients are purified for CD34+ cells, and then the 
cells are transplanted into NOD/SCID mice. 
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1.6 Cancer stem cells 
Cancer stem cells (CSCs) constitute a subpopulation of malignant cells capable of self-
renewal and differentiation45-51.  In the mid-1990s, seminal work by Dick and colleagues 
identified a stem cell-like population from a human acute myeloid leukemia (AML). 
They demonstrated that these cells were capable of transferring AML into an 
immunodeficient mouse host.  The isolated cells were CD34+CD38-, which were similar 
to the cell-surface phenotype of normal SCID-repopulating cells.  They showed that these 
stem-like cells were capable of initiating human AML in NOD/SCID mice.  In addition, 
the data they collected suggested that normal primitive cells, rather than committed 
progenitor cells, are targets for leukemic transformation52,53. These cells homed to the 
bone marrow and proliferated extensively in response to in vivo cytokine treatment, 
resulting in a pattern of dissemination and leukemic cell morphology similar to that seen 
in the original patients. The frequency of CD34+CD38- cells in the peripheral blood of 
AML patients was one engraftment unit in 250,000 cells 52,53. Recently, CSCs have been 
defined by their ability to recapitulate the generation of a continuously growing tumor. 
Weissman and colleagues proposed that a candidate CSC population should exhibit the 
following properties: 1) The unique ability to engraft; 2) The ability to recapitulate the 
tumor of origin both morphologically and immunophenotypically in xenografts; and 3) 
The ability to be serially transplanted 54. 
 
1.7 Leukemia stem cells in CML 
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CML is a stem cell disease that results in the clonal expansion of BCR-ABL-
expressing cells. In CML patients, a leukemic clone typically includes cells belonging to 
all of the myeloid lineages and also frequently includes some B cells. BCR-ABL occurs 
in a pluripotent hematopoietic stem cell, and LSCs in CML could be defined as part of 
properties of normal hematopoietic stem cells (HSCs). Eaves and colleagues isolated 
various subpopulations of CD34+ cells from CML patients, and cells in each of the 
CD34+ subpopulations were examined for the presence of BCR-ABL mRNA. BCR-ABL 
mRNA could be found in CD34+CD38- and CD34+CD38+ cells 55. Furthermore, Dick, 
Eaves and colleague reported that enriched CD34+ cells from patients with CML could be 
transplanted into NOD/SCID mice 42, although the mice did not develop lethal CML-like 
disease. The failure of BCR-ABL to induce typical CML in NOD/SCID mice does not 
necessarily indicate that this model is not suitable for examining LSCs, as human 
leukemia cells were indeed transplanted and survived in the recipient mice. It is obvious 
that the use of a NOD/SCID strain that allows more efficient engraftment of donor cells 
would likely improve the engraftment of human CML cells 56. A full understanding of the 
biology of LSCs requires the development of a good animal model that allows analysis of 
CML LSCs in the future. 
1.7.1 Identification of BCR-ABL expressing HSCs as LSCs in chronic phase CML in 
mice 
Unsuccessful induction of CML in NOD/SCID mice by engrafting human CML 
cells calls for the establishment of a more efficient CML mouse model for studying the 
biology of LSCs. In this regard, the BCR-ABL retroviral BMT mouse model has been 
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used frequently. An initial step is to identify LSCs in CML mice. Toward this goal, bone 
marrow cells from wild type mice were transduced with a retrovirus expressing BCR-
ABL and sorted by FACS into two separate populations, Sca-1- or Sca-1+, and then these 
two populations of cells were transferred into respective wild type recipient mice. Only 
the mice receiving BCR-ABL-transduced Sca-1+ cells developed and died of CML 26, 
indicating that the Sca-1+ population contains LSCs. To further narrow down the specific 
cell lineages that function as LSCs in the Sca-1+ population, BCR-ABL-expressing HSCs 
were sorted and transplanted into syngeneic recipient mice. These recipient mice 
developed and died of CML. This observation suggests that LSCs reside in BCR-ABL-
expressing HSC population. To confirm definitively that BCR-ABL-expressing HSCs are 
LSCs of chronic phase CML, bone marrow cells were isolated from primary CML mice, 
and BCR-ABL-expressing HSCs were FACS-sorted and transplanted into secondary 
recipient mice.  These mice also developed and died of CML, providing conclusive 
evidence that BCR-ABL-expressing Lin-c-Kit+Sca-1+ cells function as LSCs in chronic 
phase CML 26. 
1.7.2 Identification of granulocyte macrophage progenitors (GMP) as LSCs in blast 
crisis CML 
CML chronic phase is pathologically different from CML in blast crisis. This 
difference may be reflected in the difference of LSCs between these two disease stages. 
The expansion of the progenitor pool (CD34+Lin-) was found in bone marrow from 
patients with CML in blast crisis, whereas the population of HSCs (CD34+CD38-
CD90+Lin-) did not show an expansion 57, suggesting that LSCs for blast crisis CML 
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reside in more differentiated progenitor cells.  In support of this idea, real-time PCR 
showed that BCR-ABL transcripts were more abundant in myeloid progenitors than 
HSCs. Furthermore, a mouse model which expressed BCR-ABL in an established line of 
E2A-knockout mouse bone marrow cells also showed that BCR-ABL transformed GMPs 
function as LSCs 58. Although Wnt/β-catenin pathway is normally active in HSCs but not 
in GMPs, a striking increase in activated β–catenin was found in GMPs from CML 
patients in blast crisis and from mice with blast crisis57 58. These results demonstrate that 
GMPs function as LSCs in CML blast crisis, and these stem cells are similar to LSCs in 
AML 51. 
Different properties of LSCs in chronic phase and blast crisis CML may be the 
cause of the difference between these two disease phases (Table. 1). Identification of 
LSCs in CML provides a powerful assay system for studying the effect of BCR-ABL 
kinase inhibitors on LSCs and for identifying critical genes/pathways in these stem cells. 
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Table 1. Comparison of the different properties of LSCs between chronic-phase and 
blast-crisis CML. 
 
 
 
 
 
 
 
 
 
 
 
 
 Chronic-phase CML Blast-crisis CML 
LSCs BCR-ABL transformed HSCs BCR-ABL transformed GMP 
Human LSC markers CD34+CD38-CD90+Lin- CD34+CD38+Lin- 
Mouse LSC markers Lin-c-Kit+Sca-1+ Lin-c-Kit+Sca-1-FcγR+ 
Activation of Wnt/ β-catenin Yes Yes 
Other oncogenic mutations Unclear Yes 
Treatment Imatinib Chemotherapy or BMT 
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1.7.3 LSCs are resistant to BCR-ABL kinase inhibitors 
The BCR-ABL kinase inhibitor imatinib was developed to treat CML and now serves as 
the frontline therapy for the patients with chronic phase CML 19.  Despite its ability to 
control CML, imatinib does not appear to cure the disease, as LSCs evade treatment.  In 
one report, Holyoke and colleagues isolated Lin-CD34+ stem cells from the peripheral 
blood of patients with CML in chronic phase, and cultured the cells with and without 
growth factors, and in the presence or absence of imatinib.  They observed that imatinib 
killed almost all dividing cells; however, a significant population of viable CD34+ cells 
were unaffected by the treatment and were confirmed to be leukemic in nature 25. The 
fact that imatinib could not target the quiescent BCR-ABL-expressing LSCs made it 
apparent that imatinib treatment alone could not cure CML 21,25. Both in vitro and in vivo 
studies revealed that CD34+ cells derived from the bone marrow of CML patients could 
not be effectively killed by imatinib treatment.  CD34+ CML stem cells, especially the 
non-dividing CD34+ cell population, were not sensitive to imatinib-inhibition in vitro, 
and this was further confirmed by the detection of BCR-ABL mRNA transcripts in 
CD34+ bone marrow cells from CML patients after a long-term treatment with imatinib 
21,25. The minimal effect of BCR-ABL kinase inhibitor on LSCs was also observed in the 
CML mouse model 26. 
The second generation CML drug dasatinib, a dual BCR-ABL/SRC kinase 
inhibitor, effectively controls CML in patients.  In CML mouse model, mice treated with 
dasatinib lived significantly longer than those treated with imatinib 26.  These survival 
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data correlated with significantly lower numbers of BCR-ABL-expressing leukemic cells 
in peripheral blood compared with placebo- and imatinib-treated mice. However, all 
dasatinib-treated CML mice eventually died of this disease, indicating that like imatinib, 
this drug does not completely eradicate LSCs in CML mice. This conclusion on the 
failure of dasatinib to eradicate LSCs is supported by the observation that quiescent 
human CD34+CD38- CML cells are resistant to dasatinib treatment 59. As mentioned 
above, human CML cells did not induce typical CML in NOD/SCID mice, questioning 
whether these quiescent human CD34+CD38- CML cells are true LSCs in CML, which 
needs to be further addressed in the future. However, BCR-ABL-expressing HSCs 
(GFP+CD34-c-Kit+Hoe-) exists in the side population of bone marrow cells from the 
imatinib- or dasatinib-treated CML mice, and this cell population can efficiently transfer 
CML to recipient mice 26. This observation indicates that neither imatinib nor dasatinib 
completely eradicates BCR-ABL-expressing HSCs, suggesting that neither drug alone 
will cure CML and targeting of multiple pathways in LSCs is required to cure the disease. 
When LSCs in dasatinib-treated CML mice were further analyzed by identifying the 
GFP+Lin-c-kit+Sca-1+ population, compared with placebo-treated mice, dasatinib-treated 
mice exhibited fewer LSCs, which are likely dividing rather than quiescent.  Despite this, 
dasatinib treatment failed to eradicate these cells completely in CML mice 26. 
In mice that were treated with BCR-ABL kinase inhibitors and eventually 
succumbed to CML, there was a continuous accumulation of imatinib- or dasatinib-
insensitive LSCs in the bone marrow, which might ultimately lead to an accumulation of 
proliferating leukemic cells in the bone marrow and lungs. LSCs in bone marrow of 
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imatinib-treated CML mice were further measured at multiple time points in the course of 
the disease 27. BCR-ABL promoted self-renewal of LSCs and increased the number of 
LSCs in placebo-treated CML mice. Although this BCR-ABL-driven increase in the 
number of LSCs could be inhibited to a lower level by imatinib treatment, total numbers 
and percentages of LSCs in bone marrow of the treated mice gradually increased during 
imatinib treatment. Undefined pathways that could not be inhibited by imatinib exist, and 
contribute to the maintenance, survival, and self-renewal of LSCs. To further demonstrate 
the minimal effect of imatinib on LSCs, Sca1+ cells derived from the bone marrow of 
primary CML were transplanted into secondary recipient mice to induce secondary CML. 
Cohorts of these secondary recipients were then treated for varying durations of time. 
Then the same number of bone marrow cells from these secondary CML mice was 
transferred into syngeneic tertiary recipients.  A comparison of disease latencies among 
these different groups of recipient mice revealed that the longer the duration of imatinib 
treatment in the secondary CML mice, the more rapid the induction of tertiary CML27, 
further demonstrating that imatinib is unable to suppress LSCs, and with time, LSCs 
continue to accumulate and cause rapid death of CML mice. 
While it is still unclear why imatinib and dasatinib do not completely eradicate 
LSCs, several reasons should be excluded.  The first, the notion that the drug cannot 
access stem cells is incorrect, as inhibition of intracellular BCR-ABL phosphorylation by 
dasatinib in the stem cells were detected 26. The second, the inability of dasatinib to cure 
CML mice is not attributable to the appearance of BCR-ABL-T315I resistant clone in the 
mice because CML mice treated with dasatinib for about 3 months contained >40% of 
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GFP+Gr-1+ cells, among which there were large numbers of LSCs. Sequencing analysis 
of isolated genomic DNA from bone marrow cells of these mice did not show the T315I 
mutation in the BCR-ABL kinase domain 26. In addition, the failure of imatinib to 
eradicate LSCs is not related to the c-kit function, because both imatinib and dasatinib 
inhibit c-kit 60. These results suggest that inhibition of BCR-ABL kinase activity alone is 
insufficient to eradicate LSCs 27. 
 
1.8 Critical molecular pathways in LSCs 
BCR-ABL appears to play a critical role in the maintenance of survival of LSCs, 
as all critical molecular pathways identified so far can be activated by BCR-ABL. It is 
reasonable to think that the stemness of BCR-ABL-expressing HSCs is maintained by a 
complex molecular network involving BCR-ABL and its interaction with other 
downstream signaling pathways. If this were the case, these pathways would be 
specifically involved in the survival regulation of LSCs but not normal stem cell 
counterparts. In other words, it is possible to identify genes that play critical role in the 
regulation of LSC function. This idea is supported by the identification of the Alox5 gene 
as a key regulatory gene for LSCs but not normal hematopoietic stem cells. So far, there 
have been no data that do not support a role of BCR-ABL in the maintenance of the 
stemness of LSCs. However, a critical question to ask is why BCR-ABL kinase inhibitors 
such as imatinib and dasatinib are incapable of eradicating LSCs, if BCR-ABL kinase 
activity is inhibited? It has been shown that the inhibition of BCR-ABL kinase activity by 
imatinib in LSCs does not completely compromise BCR-ABL function26, indicating the 
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kinase-independent function of BCR-ABL. A complete removal of BCR-ABL protein 
would have a much stronger inhibitory effect on LSCs. Besides targeting BCR-ABL, the 
identification and inhibition of key BCR-ABL downstream signaling molecules/pathways 
will offer effective therapeutic strategies aiming to eradicate LSCs. Below are some 
examples of the key pathways activated by BCR-ABL in LSCs (Figure 4). 
 
 
 
Figure 4. Critical molecular pathways in LSCs 
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1.8.1 Wnt/β-catenin pathway 
Wnt/β-catenin signalling plays an important role in HSC development 61. β-
catenin is a key factor in this pathway, and its activation upon the Wnt ligand binding to 
the receptor and its stability after activation are highly regulated by a destruction complex 
involving the tumor suppressor adenomatous polyposis coli (APC), the scaffolding 
protein that binds newly synthesized β-catenin, and two kinases choline kinase (CKI) and 
glycogen synthase kinase 3β (GSK3β) which phosphorylate a couple of Ser and Thr 
residues in the amino terminus of β-catenin62. The phosphorylated β-catenin recruits an 
E3 ubiquitin ligase, which targets β-catenin for proteasomal degradation 63. In blast crisis 
CML patient, β-catenin is activated in myeloid progenitors and the activated β-catenin 
translocates to the nucleus 57. In a CML mouse model, loss of β-catenin delays the 
development of CML 27,64. The delayed CML development in the absence of β-catenin is 
due to a decreased ability of BCR-ABL to support long-term renewal of LSCs, as shown 
in the serial replating and transplantation assays. The inhibitory effect of β-catenin 
deletion on LSCs is associated with the reduction of the levels of p-Stat5α instead of 
CEBPα, Id1, Pax5, cyclinD1, cyclinD2 or c-Myb 64. Recently, Wnt/β-catenin signaling 
pathway has also been shown to be required for the development of LSCs in AML, which 
derived from either HSC or more differentiated GMPs 65. 
1.8.2 Hedgehog pathway 
The Hedgehog (Hh) genes have been identified for their roles in Drosophila 
development, as mutations in the Hh genes alter the segmental pattern of the larva and 
cause embryonic lethality 66. Three homologs of Hh genes (Sonic hedgehog (Shh), Indian 
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hedgehog (Ihh) and Desert hedgehog (Dhh)) have been identified in mammalian system 
67-69.  The Hh proteins are secreted proteins and can mediate signal transduction in nearby 
and distant tissues by binding to their specific receptor, Patched (PTC). PTC is a 
transmembrane protein that negatively regulates another transmemberane protein, 
smoothened (SMO). When SMO is released from the inhibition of PTC, it eventually 
activates its downstream Gli transcription factor; Gli in turn regulates expression of its 
target genes, including Gli1 and Ptch 70-72. 
Hh signaling has also been indicated during primitive hematopoiesis based on 
mouse embryonic stem cell studies. Ihh is a primitive endoderm-secreted signal, and is 
sufficient to activate embryonic hematopoiesis and vasculogenesis in pre- or early-
gastrulation-stage epiblasts73. Moreover, study from zebrafish showed that the mutations 
of the Hh pathway members or inhibition of Hh pathway with the Hh inhibitor 
cyclopamine can cause a developmental defect in adult HSCs 74. However, likely due to 
the functional redundancy of the three Hh members, the individual Hh knockout mice do 
not have a significant defect in adult hematopoiesis 75,76. In additon, the activation of Hh 
pathway has been observed in different human cancers. Activating point mutations of 
Smo or inactivating point mutations of Ptch have been detected in medulloblastoma, 
rhabdomyosarcoma  and sporadic basal cell carcinoma 77-79. In CML patients, more than 
4-fold induction of transcript levels for Gli1 and Ptch1 was observed in CD34+  cells in 
both chronic phase and blast crisis 80. In two studies using a CML mouse model, 
recipients of BCR-ABL transduced bone marrow cells from Smo-/- donor mice developed 
CML significantly slower than recipients of BCR-ABL transduced bone marrow cells 
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from wild type donor mice 80,81. When the frequency and function of LSCs were further 
examined, Smo deletion caused a significant reduction of the percentage of LSCs. In 
contrast, overexpression of Smo led to an increased percentage of LSCs and accelerated 
the progression of CML 80,81. The underlying mechanism for the inhibitory effect of the 
Smo deletion on LSCs is likely through regulating the cell fate determinant Numb, 
because the Smo deletion causes an upregulation of Numb expression in LSCs and 
overexpression of Numb inhibits the propagation of LSCs in vitro 81. 
 
1.8.3 Alox5 pathway 
The Alox5 gene encoding arachidonate 5-lipoxygenase (5-LO) is involved in 
numerous physiological and pathological processes, including oxidative stress response, 
inflammation and cancer 82-89. 5-LO is responsible for producing leukotrienes, a group of 
inflammatory substances that cause human asthma 90. Altered arachidonate metabolism 
by leukocytes and platelets was reported in association with MPD almost 30 years ago 91. 
Several selective 5-LO inhibitors were found to reduce proliferation of and induce 
apoptosis of CML cells in vitro 92,93, although potential off-target effects of these 
inhibitors were not excluded in these studies. Recently, human CML microarray studies 
have shown that Alox5 is differentially expressed in CD34+ CML cells, suggesting a role 
of Alox5 in human CML stem cells 28,29. However, the function of Alox5 in LSCs needs to 
be tested. A microarray analysis of gene expression in LSCs in CML mice showed that 
the Alox5 gene was upregulated by BCR-ABL and that this upregulation was not 
inhibited by imatinib treatment 37, providing a possible explanation why LSCs are not 
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sensitive to inhibition by BCR-ABL kinase inhibitors 26. Furthermore, recipients of BCR-
ABL transduced bone marrow cells from Alox5-/- donor mice were resistant to the 
induction of CML by BCR-ABL 37, demonstrating that Alox5 is essential for CML 
development. FACS analysis of CML cells from the peripheral blood and bone marrow 
of recipients receiving BCR-ABL-transduced Alox5-/- donor bone marrow cells showed 
that myeloid leukemia cells proliferated initially, peaking around 2 weeks, then started to 
decline, and eventually disappeared after 7 weeks. Alox5 deficiency mainly affected 
growth of BCR-ABL-expressing but not non-BCR-ABL-expressing donor bone marrow 
cells, suggesting that Alox5 signaling is much more critical for the function of LSCs than 
for normal HSCs. The effect of Alox5 on LSC function was further demonstrated and 
supported by the failure of BCR-ABL-expressing Alox5-/- bone marrow cells to induce 
CML in secondary recipient mice 37. Together, these results suggest that Alox5 could be a 
specific target gene in CML LSCs. This idea was tested by treating CML mice with 
Zileuton, an inhibitor of 5-LO (see below). 
1.8.4 Pten pathway 
Besides Alox5, another important gene identified from the microarray analysis of 
LSCs of CML mice is phosphatase and tensin homolog (Pten).  Recently, gene 
expression profiling in HSCs of chronic phase CML patients was found to be similar to 
that seen in normal myeloid progenitor cells, and Pten was found to be differentially 
expressed 30. Pten is often deleted or inactivated in many tumor types, including 
glioblastoma, endometrial carcinoma, and lymphoid malignancies 94-96. PTEN is a 
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phosphatase that dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate(PIP3) in 
PI3K signaling pathway 97. PI3K is a key signaling pathway for cell growth, anti-
apoptosis, cell division and glucose uptake98-100. PI3K is a family of proteins that catalyze 
transfer of the phosphate of ATP to the D3 position of phosphoinositides. Activated PI3K 
translocates to the plasma membrane and associates with a receptor tyrosine kinase or its 
substrates. The activated PI3K produces phosphoinositide-3-phosphate and/or 
phosphoinositide-3,4,5-triphosphate and  those PI3K’s products activates downstream 
signaling pathways, including PDK, AKT and PKC101-103. Phosphatases like PTEN can 
degrade those phosphoinositide-3-phosphate products and further inhibit the cell growth. 
PIP3 is a direct product of PI3K and plays a critical role in the regulation of cell survival 
and growth through the activation the serine/threonine protein kinase PDK1 and its 
downstream target AKT 104. A study shows that PTEN is oxidized and inactivated in 
pancreatic cell lines, and that treatment with a 5-LO inhibitor prevented PTEN 
degradation 105, suggesting that 5-LO reduces the stability of PTEN and that Pten is 
functionally related to Alox5. To reveal the role of PTEN in LSCs, Pten were deleted 
from bone marrow cells of Ptenflox/flox mice through the retroviral transduction of cells 
with a tricistronic cassette expressing BCR-ABL, iCre, and GFP (BCR-ABL-iCre-GFP) 
106. Bone marrow cells from Ptenflox/flox mice were transduced with BCR-ABL-iCre-GFP 
or BCR-ABL-GFP retrovirus, followed by transplantation of the transduced cells into 
recipient mice. Without Pten, CML developed much faster, which correlated with an 
increased percentage of GFP+Gr-1+ myeloid leukemia cells and an increased number of 
leukemia cells in peripheral blood of the mice 106. The effect of Pten on the function of 
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LSCs was tested by comparing the ability to induce CML between LSCs that expressed 
BCR-ABL-PTEN-GFP and those that expressed BCR-ABL-GFP. The same number of 
LSCs cells sorted from CML mice receiving either BCR-ABL-GFP or BCR-ABL-PTEN-
GFP transduced bone marrow cells were transplanted into recipient mice. The number of 
leukemia cells in CML mice receiving BCR-ABL-PTEN-GFP transduced LSCs was 4-
fold lower than that in CML mice receiving BCR-ABL-GFP transduced LSCs.  
Consistent with the less severe CML phenotype, survival of mice receiving LSCs 
transduced with BCR-ABL-PTEN-GFP was significantly longer than that of mice 
receiving LSCs transduced with BCR-ABL-GFP 106, indicating that PTEN suppresses the 
function of LSCs. An attractive idea to test in the future is whether Alox5 deficiency leads 
to an upregulation of Pten in CML mice and whether the lack of CML development in 
the absence of Alox5 is at least partially related to the upregulation of Pten. 
1.8.5 FoxO pathway 
The FOXO (Forkhead O) subfamily of transcription factors plays critical roles in 
cell cycle arrest, stress resistance and apoptosis 107. There are four members (FOXO1, 
FOXO3, FOXO4 and FOXO6), and they are functionally downstream of the PI3K-AKT 
pathway108,109. AKT directly phosphorylates FOXOs members, resulting in the exclusion 
of FOXOs from the nucleus and degradation in cytoplasma 110. FOXOs localize to 
nucleus and regulate apoptosis, cell cycle progression and oxidative stress responses 110-
113. Although individual knockout mice of FoxO1 and FoxO4 did not demonstrate overt 
hematopoietic phenotype, FoxO1/3/4 triple conditional knockout mice showed the 
essential role of FoxOs in maintaining self-renewal capacity of HSCs108,109, shown by a 
30 
 
marked decrease of the HSC compartment (including the short- and long-term HSC 
populations)  in FoxO-deficient mice. The defective long-term repopulating capability of 
HSCs in FoxO-deficient mice was shown to be correlated with increased cell division and 
apoptosis of HSCs 108. FoxO transcription factors have also been shown to play essential 
roles in the maintenance of CML LSCs. FOXO3a localizes to the nucleus of cells and 
causes decreased Akt phosphorylation in LSC population 114. In addition, serial CML 
transplantation showed that the FoxO3a deficiency severely impairs the ability of LSCs 
to induce CML 114. Furthermore, TGF-β is a critical regulator of Akt activation and 
controls FoxO3a localization in LSCs of CML. A combination strategy of TGF-β 
inhibition, FoxO3a deficiency and BCR-ABL kinase inhibition results in an efficient LSC 
depletion and suppresses CML development 114. 
1.8.6 Msr1 pathway 
MSR1 is a member of a family termed scavenger receptors and is mostly expressed in 
macrophages and dendritic cells and bind to a broad range of ligands including Ac-LDL, 
bacterial surface components and apoptotic cells115. MSR1 could mediate receptor 
internalization and cell adhesion and play important roles in host cell interactions, 
macrophage adhesion and phagocytosis of apoptotic cells115. The binding MSR1 will 
activate a series of signal pathways, including Src kinase pathway and PI3K kinase-Akt 
pathway, to promote the cell growth, metabolism, survival and glucose homeostasis116. 
The Src kinase Lyn is associated with the cytoplamic domain of MSR1, and MSR1 will 
rapidly activate Lyn117. Another important signal pathway is PI3K-AKT pathway. PI3K-
AKT-GSK3β pathway was activated rapidly during the MSR1 mediated cell adhesion116. 
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Recently, MSR1 was reported to be associated with prostate cancer in men of both 
African American and European genetically although the mechanism of MSR1 regulating 
cancer development is still unclear118. In CML development, Msr1 is down-regulated by 
BCR-ABL and this down-regulation is partially restored by Alox5 deletion, and that Msr1 
deletion causes acceleration of CML development. Moreover, Msr1 deletion markedly 
increases LSC function through its effects on cell cycle progression and apoptosis. Msr1 
affects CML development through the PI3K-AKT pathway and β-Catenin. The 
enhancement of Msr1 function may be of significance in the development of novel 
therapeutic strategies targeting CML. 
1.9 Therapeutic strategies for eradicating LSCs in CML 
1.9.1 Changing cellular properties of LSCs 
Because BCR-ABL kinase inhibitors only kill proliferating leukemia cells, one 
potential strategy is to stimulate the proliferation of LSCs by stimulating primitive 
quiescent CML cells into cell cycle. Taking advantage of the role of G-CSF (granulocyte-
colony stimulating factor) in promoting cell cycle entry 119, treatment with G-CSF, in 
combination with imatinib, provides a novel method for treating CML, although current 
efforts did not result in expected outcome 120. Another attractive approach is to inhibit 
autophagy of LSCs using inhibitory compounds such as chloroquine 121, because 
inhibition of autophagy may promote cell death induced by imatinib 121. Finally, Pandolfi 
and colleagues discovered that non-proliferating LSCs lacking the tumor suppressor 
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promyelocytic (PML) leukemia protein tends to enter cell cycle quickly, leading to LSC 
exhaustion 122. 
1.9.2 Targeting critical signaling pathways in LSCs 
1.9.2.1 Zileuton. Novel approaches aimed at inhibiting LSCs may more efficiently 
curtail leukemogenesis and hold real potential for curative therapy. Recently, this strategy 
has been applied to the development of an effective drug to eradicate LSCs in AML using 
an in silico screen of public gene expression database 123. As described above, using 
CML mice, a genetic study showed the essential role of Alox5 in survival of LSCs but not 
normal hematopoietic stem cells 37. 5-LO as a potential target in LSCs for treating CML 
was further tested by treating CML mice with a placebo, the 5-LO inhibitor Zileuton, 
Imatinib alone, or both Zileuton and Imatinib in combination. As expected, Imatinib 
treatment was effective in treating CML, but Zileuton treatment was even more effective 
than Imatinib. Treatment of CML mice with both Zileuton and Imatinib had a better 
therapeutic effect than with either drug alone in prolonging survival of the mice. 
Prolonged survival of Zileuton-treated CML mice correlated with less severe leukemia 
cell infiltration to the lungs and the spleens. In peripheral blood of CML mice treated 
with Zileuton and Imatinib, myeloid leukemia cells gradually decreased with treatment, 
and importantly, Zileuton treatment did not have an inhibitory effect on normal myeloid 
cells in peripheral blood of the same animals, as the number of these non-leukemic cells 
increased during the treatment. In the bone marrow of Zileuton-treated CML mice, 
myeloid leukemia cells were also significantly reduced during the treatment. Prolonged 
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survival of CML mice by Zileuton treatment is consistent with the targeted inhibitory 
effect of Zileuton on LSCs. During the treatment, the ratio between the percentage of LT 
(long-term)-LSCs and that of ST (short-term)-LSCs/ multiple progenitor cells (MPP) 
cells increased, suggesting a possible blockade of differentiation of LT-LSCs. Zileuton 
treatment did not affect differentiation of GFP-LT-HSCs in the same animals, 
demonstrating that inhibition of 5-LO did not suppress normal HSCs. These results 
clearly demonstrate that Alox5 is a promising target gene for eradicating LSCs in CML. 
A Phase I/II study at University of Massachusetts Medical School (Worcester, 
Massachusetts, USA) to evaluate the safety of Zileuton in combination with imatinib in 
chronic phase CML patients has been approved by FDA, and the effectiveness of this 
novel anti-LSC therapy remains to be seen in near future. 
1.9.2.2 IPI-504. Inhibition of the chaperone protein HSP90 may prove effective in 
disrupting LSC function, as treatment of BCR-ABL-expressing cells with the HSP90 
inhibitor 17-AAG suppresses cell growth and induces apoptosis 124. Recently, a newly 
developed HSP90 inhibitor IPI-504 was used to investigate whether HSP90 is an 
effective target for inhibiting LSCs and for the treatment of CML in vivo in CML mouse 
model 125.  The results showed that HSP90 stabilizes the BCR-ABL and mutant (T315I) 
BCR-ABL oncoproteins and that treatment with IPI-504 significantly prolonged survival 
of mice with wild type BCR-ABL induced CML but even more markedly prolonged 
survival of mice with the T315I BCR-ABL-induced CML.  Impairment of LSC function 
by IPI-504 was also investigated by culturing CML bone marrow cells under the 
conditions that support survival and growth of HSCs 125. FACS analysis showed that 
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compared with the untreated group, imatinib treatment did not reduce the percentage or 
number of LSCs, whereas IPI-504 treatment had a dramatic inhibitory effect on LSCs. 
The inhibitory effect of IPI-504 on LSCs was also observed in vivo by FACS analysis of 
LSCs, and IPI-504 treatment reduced the percentage and number of LSCs in bone 
marrow. When normal mice were treated with IPI-504 or placebo for 2 weeks, and 
analysis of bone marrow from these mice showed that there were no changes in levels of 
normal HSCs from any treatment groups, indicating that IPI-504 treatment did not inhibit 
survival of normal HSCs. 
1.9.2.3 Omacetaxine. Omacetaxine (formerly known as homoharringtonine) is a 
cephalotaxine ester derived from the evergreen tree, Cephalotaxus harringtonia, and 
native to China. Omacetaxine has shown clinical activity alone and in combination with 
imatinib in CML patients resistant to imatinib or other tyrosine kinase inhibitors 126. 
Recently, omacetaxine has been shown to have the capability to kill LSCs effectively in 
vitro and in CML mice 127. When mice with BCR-ABL-induced CML were treated with 
omacetaxine, a significant reduction in total LSCs and overall leukemic cells was 
observed. Because its mechanism differs from tyrosine kinase inhibitors, omacetaxine 
also showed an inhibitory effect on LSCs expressing imatinib-resistant BCR-ABL-T315I. 
Interestingly, omacetaxine is more effective in treating BCR-ABL-T315I induced CML 
than treating wild type BCR-ABL-induced CML, which is consistent with the result from 
an earlier in vitro study 128. The underlying mechanism for the inhibitory effect of 
omacetaxine on LSCs is still unknown, although several potential pathways are thought 
to be involved, including HSP90, BCL-2 and MCL-1127.  The clinical efficacy of 
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omacetaxine on CML could be related to the inhibitory activity of omacetaxine on LSCs 
127. 
1.9.2.4 Cyclopamine. Cyclopamine belongs to the jervine family of alkaloids derived 
from the plants of genus Veratrum, and is a specific Hedgehog inhibitor 129.  
Cyclopamine inhibits the Hh pathway by binding directly to Smo and affecting its protein 
conformation 130.  When BCR-ABL induced CML mice were treated with cyclopamine, 
the untreated animals died of CML within 4 weeks, but 60% of the treated mice were still 
alive after 7 weeks 130. In addition, cyclopamine-treated mice had up to a 14-fold 
reduction in LSC population. Furthermore, cyclopamine was effective in treating mice 
with BCR-ABL-T315I induced CML. These results indicate that the Hh pathway is 
required for the functional regulation of LSCs, and cyclopamine may be an effective drug 
for treating human CML, although its effect on normal HSCs needs to be evaluated 
further 81. 
1.9.2.5 BMS-214662. BMS-214662 is a cytotoxic farnesyltransferase inhibitor capable of 
targeting and killing non-proliferating tumor cells 131. BMS-214662, alone or in 
combination with imatinib or dasatinib, induces apoptosis of both proliferating and 
quiescent primitive CD34+CD38- CML stem cells with much less effect on normal 
CD34+ HSCs 44. The selective inhibitory effect of BMS-214662 on CML stem cells may 
not be related to its anti-farnesyltransferase activity, as BMS-225975, a structurally 
similar farnesyltransferase inhibitor, did not inhibit CML stem cells. The apoptotic 
pathways involved in the inhibitory effect of BMS-214662 include Bax, reactive oxygen 
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species, Cytochrome c, and Caspase-9/3. These pathways were coupled with protein 
kinase Cβ (PKCβ), E2F1 and Cyclin A-associated Cyclin-dependent kinase 2. Co-
treatment of CML CD34+ and CD34+CD38- cells with the PKC modulators, bryostatin-1 
or hispidin, markedly decreased these early events and the subsequent apoptosis. These 
results indicate that BMS-214662 may provide a molecular framework for the 
development of novel therapeutic strategies 44,132. 
1.9.2.6 FTY720. Protein phosphatase 2A (PP2A) is a tumor suppressor.  The phosphatase 
activity of PP2A is inhibited by the BCR/ABL-induced expression of the PP2A inhibitor 
SET 133. FTY720 is a water-soluble, nontoxic PP2A activator with a high oral 
bioavailability, and has been used as an immunomodulator in Phase III trials for patients 
with multiple sclerosis 134,135. Recently, the therapeutic effect of FTY720 was tested in 
CML, and FTY720 was shown to activate PP2A and suppress BCR/ABL in myeloid and 
lymphoid cell lines. In human LSCs, PP2A activity was reduced by 90% in CML CD34+ 
cells compared to CD34+ cells from normal bone marrow donor. The CD34+cells from 
CML patients were cultured in the presence of myeloid cytokines. After treatment with 
FTY720, the PP2A activity was shown to be recovered to the levels in normal CD34+ 
cells 136.  In addition, FTY720 treatment triggers apoptosis of LSCs, showing a great 
potential for targeting LSCs through activating PP2A. 
1.9.2.7 Bortezomib. The proteasome is an intracellular organelle providing a targeted 
mechanism for protein degradation via 3 catalytic specificities: chymotrypsin-like (CT-L), 
trypsin-like (T-L), and post-glutamyl hydrolytic (PG); this process is essential for cell 
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cycle progression, cell proliferation and apoptosis 137,138. Bortezomib is a reversible and 
specific inhibitor of CT-L activity, and has been used for treating mantle cell lymphoma 
and multiple myeloma 139. Proteasomal activity was shown to be increased in CML cells 
138, and loss of proteasomal activity showed an inhibitory effect on growth of BCR-ABL+ 
cell lines sensitive or resistant to imatinib 140.  The effect of bortezomib was also tested in 
CD34+ cells from CML patients. In vitro, bortezomib selectively inhibited colony 
formation by CD34+ BCR-ABL+ progenitor cells 141. Bortezomib was also shown to 
induce apoptosis and inhibit proliferation of CD34+38-, long-term culture-initiating 
(LTC-IC) cells 142. Bortezomib also impaired the function of CML LSCs by reducing the 
engraftment of patient-derived CD34+ CML cells142. Importantly, different BCR-ABL 
mutants, including T315I, H396P and M351T, were sensitive to bortezomib 38, although 
it also inhibited proliferation and induced apoptosis of normal CD34+38- cells 142. 
1.9.2.8 Interferon-α (IFN-α). Interferon-α, an immunomodulatory cytokine, has been 
used to treat CML 143. Although the underlying mechanism is unclear, IFN-α may target 
LSCs.  In a study involving 12 CML patients who achieved molecular remission on 
imatinib and subsequently discontinued the kinase inhibitor therapy, half of them 
relapsed with detectable BCR-ABL mRNA transcripts, whereas the others remained in 
molecular remission. All these patients remaining in molecular remission had been 
previously treated with IFN-α 22. These results are not definitive, but suggest a potential 
inhibitory effect of IFN-α on LSCs in CML. More work needs to be done to explain how 
IFN-α inhibits LSCs. 
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In summary, although current understanding of the biology of LSCs in CML is still 
preliminary, the identification of several critical target genes such as Alox5, hedgehog, β-
cantenin and FoxO provides opportunities for developing promising anti-stem cell 
therapies for curing CML. Future clinical trials for these drugs will determine whether 
this anti-stem cell strategy is effective in the treatment of CML and perhaps other cancers. 
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CHAPTER II 
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced 
chronic myeloid leukemia and acute lymphoblastic leukemia in mice. 
The work described in this chapter has been published (Chen Y, Hu Y, Michaels S, Segal 
D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-
ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. 
Leukemia. 2009, 23(8):1446-54) 
 
2.1 Abstract 
Omacetaxine mepesuccinate (formerly homoharringtonine) is a molecule with a 
mechanism of action that is different from tyrosine kinase inhibitors, and its activity in 
chronic myeloid leukemia (CML) seems to be independent of the BCR-ABL mutation 
status. Using BCR-ABL-expressing myelogenous and lymphoid cell lines and mouse 
models of CML and B-cell acute lymphoblastic leukemia (B-ALL) induced by wild-type 
BCR-ABL or T315I mutant-BCR-ABL, we evaluated the inhibitory effects of 
omacetaxine on CML and B-ALL. We showed that more than 90% of the leukemic stem 
cells were killed after treatment with omacetaxine in vitro. In contrast, less than 9 or 25% 
of the leukemic stem cells were killed after treating with imatinib or dasatinib, 
respectively. After 4 days of treatment of CML mice with omacetaxine, Gr-1+myeloid 
leukemia cells decreased in the peripheral blood of the treated CML mice. In the 
omacetaxine-treated B-ALL mice, only 0.8% of the B220+leukemia cells were found in 
40 
 
peripheral blood, compared with 34% of the B220+leukemia cells in the placebo group. 
Treatment with omacetaxine decreased the number of leukemia stem cells and prolonged 
the survival of mice with BCR-ABL-induced CML or B-ALL. 
2.2 Introduction 
The Abl tyrosine kinase inhibitors (TKIs) imatinib mesylate and dasatinib, have 
revolutionized the treatment of Philadelphia-positive (Ph+) leukemia in both chronic 
myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL) by targeting 
and disabling the proliferative signal coming from BCR-ABL. These TKIs elicit high 
rates of durable complete cytogenetic responses, particularly in CML, however, only a 
small proportion of treated individuals remain disease free if therapy is discontinued22,144. 
This lack of curative effect of TKIs in Ph+ leukemias is largely due to insensitivity of 
primitive leukemic stem cells to these TKIs and the selection of cells expressing TKI 
resistant BCR-ABL mutants145.  At present, an anti-stem cell strategy has not been 
developed for treating these leukemia patients; however a number of agents such as 
farnesyl transferase inhibitors have shown activity toward leukemic stem cell that is 
superior to TKIs44,146. These findings suggest that non-TKI based therapies may prove 
useful in targeting leukemic stem cells in Ph+ leukemias and raise the prospect of 
improved rates of durable complete molecular remission.  
Omacetaxine is a cephalotaxine ester derived from the evergreen tree, 
Cephalotaxus harringtonia, native to China. The chemical structure of omacetaxine is 
shown in Supplementary Figure 1. Omacetaxine has shown clinical activity alone and 
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in combination with imatinib in CML patients resistant to imatinib or other 
TKIs126,147,148. However, little is known about whether omacetaxine has an inhibitory 
effect on leukemic stem cells. In this study, we utilized mouse model of BCR-ABL 
induced leukemia to investigate the efficacy of omacetaxine toward leukemic stem 
cells. We show that omacetaxine inhibited the proliferation of CML and B-ALL stem 
cells and provided a significant survival benefit to mice with CML and B-ALL. 
2.3 Results 
2.3.1 Omacetaxine suppresses myeloid leukemic cells and improves survival of 
mice with BCR-ABL induced CML  
To investigate the therapeutic effect of omacetaxine (Supplementary Figure 1) on CML, 
we used a bone marrow transplantation (BMT) mouse model of CML in which bone 
marrow cells from BALB/c donor mice pretreated with 5-fluorouracil (5-FU), were 
transduced with BCR-ABL and injected into BALB/c recipient mice to induce CML36. 
Mice transplanted with BCR-ABL-transduced bone marrow were treated with a 
placebo or omacetaxine. Omacetaxine treatment of CML mice decreased BCR-ABL–
expressing (GFP+) leukemia cells during therapy (Figure 1a and 1b, P < 0.001).  In 
addition, splenomegaly in omacetaxine-treated mice (a consistent physical sign in 
CML) decreased by 88%, compared to placebo (Figure 1b). All placebo-treated mice 
developed CML and died within 3 weeks after BMT. In contrast, all omacetaxine 
treated CML mice survived (Figure 1c). Lung hemorrhage caused by infiltration of 
mature myeloid leukemia cells is a major cause of death of CML mice36. We further 
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evaluated the therapeutic effect of omacetaxine on CML by examining the severity of 
lung hemorrhages at day 14 after BMT. Compared with placebo-treated mice, much 
less severe hemorrhages were observed in the lungs of omacetaxine–treated CML mice 
(Figure 1d). We compared the effect of omacetaxine on BCR-ABL-expressing and 
non-BCR-ABL-expressing 32D cells, and found that omacetaxine inhibited BCR-
ABL-expressing cells more strongly than non-BCR-ABL-expressing cells (Figure 1e). 
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Figure 1: Omacetaxine reduces circulating GFP+ cells, reduces spleen weight and 
improves survival in mice with BCR-ABL-WT-induced CML. 
a. Flow cytometric evaluation of the leukemic process in omacetaxine and placebo 
treated CML mice. Percentage of Gr-1+GFP+ cells in peripheral blood of placebo or 
omacetaxine-treated CML mice were analyzed at day 14 after BMT. b. The number of 
circulating leukemic cells (calculated as percentage of Gr-1+GFP+cells×white blood 
cell count) and spleen weight in mice with BCR-ABL induced CML treated with 
placebo or omacetaxine for 4 days was determined on day 14 after 0.5 x 106 cells 
transplantation. c.Treatment with omacetaxine prolonged the survival of CML mice. 
Mice with BCR-ABL-induced CML were treated with placebo (n=15) or omacetaxine 
(0.5 mg/kg for 4 days) (n=15).  d. Treatment with omacetaxine reduced lung 
hemorrhage and splenomegaly of mice with BCR-ABL induced CML after treatment 
with omacetaxine for 4 days. e. The inhibitory effect of Omacetaxine on 32D and 32D 
P210 cells. 32D and BCR-ABL-transduced 32D cells were cultured at 5 × 105 cells per 
well in 24-well plates, and omacetaxine (20nM) was added to the culture for 48h or 
72h. The number of viable cells at the indicated drug concentrations was determined by 
trypan blue. 
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Figure 1: Omacetaxine reduces circulating GFP+ cells, reduces spleen weight 
and improves survival in mice with BCR-ABL-WT-induced CML. 
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2.3.2 Omacetaxine suppresses chronic myeloid leukemia stem cells in vitro and in 
vivo.  
Although imatinib, the BCR-ABL inhibitor, has been shown to prolong survival of 
mice with BCR-ABL–induced CML, it does not completely stop the progression of 
CML in our BMT mouse model, due to accumulation of surviving leukemia stem 
cells26,149. The Lin– cKit+ Sca-1+ population has been identified as CML stem cells, as 
these cells confer leukemia in recipient mice in the CML model 26. To investigate 
whether omacetaxine has an inhibitory effect on leukemia stem cells, bone marrow 
cells from CML mice on day 13 after BMT were isolated and treated with omacetaxine 
at various doses in conditions that support survival and growth of hematopoietic stem 
cells(HSCs) (Figure 2a) 150,151. After 6 days in culture, survival of GFP+Lin- cKit+ Sca-
1+ cells representing leukemia stem cells, and GFP+ cells indicating BCR-ABL-
expressing cells, was determined. FACS analysis showed that compared with the 
placebo group, omacetaxine treatment inhibited survival of BCR-ABL expressing 
leukemia stem cells and total leukemia cells in a dose dependent manner (Figure 2a, P 
< 0.001).  
The effect of omacetaxine on leukemia stem cells in CML mice was also examined. Mice 
with BCR-ABL-induced CML were treated with a placebo, omacetaxine, imatinib or both 
drugs in combination for 4 days from Day 10 after BMT, and the number of GFP+Lin-
cKit+Sca-1+ and total GFP+ bone marrow cells was determined by flow cytometry. 
Consistent with our previous findings125, imatinib treatment did not lower the percentage 
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and number of leukemia stem cells and total leukemia cells in bone marrow, compared 
with the placebo group.  Omacetaxine treatment greatly reduced the numbers of both 
leukemia stem cells and total leukemia cells, while treatment of CML mice with both 
drugs did not show further effects on reducing the number of leukemia stem cells or total 
leukemia cells, compared with the mice treated with omacetaxine alone (Figure 2b). The 
effect of omacetaxine on leukemia stem cells in CML mice was also compared. With the 
effect of omacetaxine on BCR-ABL-negative stem cells in the same animals. We found 
that a higher percentage of leukemia stem cells were inhibited by omacetaxine as 
compared with the percent reduction of BCR-ABL-negative stem cells (Figure 2c).  
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Figure 2: Omacetaxine inhibits survival of leukemic stem cells in vitro and in vivo. 
a. Bone marrow cells isolated from C57BL/6 (B6) mice with BCR-ABL-induced CML 
on day 13 afternoon transplant were cultured in vitro (5 x 106 cells/6 cm tissue culture 
plate) under stem cell conditions ("Materials and Methods") in the presence or absence 
of omacetaxine (12.5 nM, 25 nM, 50 nM)) for 6 days (changing the stem cell medium 
containing placebo or omacetaxine at day 3) followed by FACS analysis of leukemia 
stem cells (GFP+Lin-cKit+Sca-1+). b. Mice with BCR-ABL–induced CML were treated 
with placebo (n=5) or omacetaxine (0.5 mg/kg, 4 days) (n=5), respectively, for 4 days 
beginning at day 10 after transplantation. Bone marrow cells were isolated from the 
treated CML mice, and leukemia stem cells were analyzed by FACS. The numbers of 
cells represents the average number of leukemia stem cells from the femur and tibia of 
each treated CML mouse. c. Mice transplanted with MSCV-GFP induced bone marrow 
cells were treated with placebo (n=3) or omacetaxine (0.5 mg/kg) (n=3), respectively, 
for 4 days beginning at day 10 after transplantation. Bone marrow cells were isolated 
from the treated mice, and hematopoietic stem cells were analyzed by FACS. The 
numbers of cells represents the average number of hematopoietic stem cells from the 
femur and tibia of each mouse. 
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Figure 2: Omacetaxine inhibits survival of leukemic stem cells in vitro and in vivo. 
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2.3.3 Omacetaxine improves survival of mice with BCR-ABL-T315I induced CML 
and suppresses BCR-ABL-T315I leukemia stem cells. 
Imatinib does not suppress leukemia cells expressing BCR-ABL-T315I and does not 
prolong the survival of mice with BCR-ABL-T315I induced CML19,125. To investigate 
whether omacetaxine also inhibits BCR-ABL-T315I induced CML and leukemia stem 
cells, we transduced bone marrow cells with BCR-ABL-T315I and implanted the 
transduced cells into BALB/c recipient mice to induce CML. Similar to wild type 
BCR-ABL induced CML, omacetaxine caused a decrease in peripheral blood BCR-
ABL-T315I–expressing (GFP+) leukemia cells (Figure 3a) and reduced splenomegaly 
(data not shown). BCR-ABL-T315I-expressing myeloid leukemic cells in peripheral 
blood of the treated CML mice were reduced greater than 49.5 fold compared to 
untreated CML mice (Figure 3a), whereas wild type BCR-ABL-expressing myeloid 
leukemic cells in peripheral blood of the treated CML mice were reduced only 30.2 
fold (Figure 1b). These results suggest that omacetaxine was more efficient in 
inhibiting BCR-ABL-T315I compared to wild type BCR-ABL, which is supported by a 
previous report128. Omacetaxine treatment prolonged the survival of mice transplanted 
with BCR-ABL-T315I expressing bone marrow cells (Figure 3b). We next examined 
whether omacetaxine could inhibit the BCR-ABL-T315I induced leukemia stem cells 
in vivo. Mice with BCR-ABL T315I- induced CML were treated with a placebo or 
omacetaxine for 4 days from Day 10 after BMT. Bone marrow and spleen cells were 
analyzed by FACS for GFP+Lin- cKit+CD34- cells. The number of BCR-ABL-T315I 
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expressing leukemia stem cells was significantly decreased by omacetaxine treatment 
(Figure 3c).     
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Figure 3: Omacetaxine improves survival of mice with BCR-ABL-T315I-induced 
CML. 
a. The number of circulating leukemia cells (calculated as percentage of Gr-
1+GFP+cells×white blood cell count) in mice with BCR-ABL-T315I–induced CML 
treated with placebo or omacetaxine was determined on day 14 after transplantation. b. 
Treatment with the omacetaxine prolonged survival of CML mice. Mice with BCR-
ABL-T315I induced CML were treated with placebo (n = 15) or omacetaxine (0.5 
mg/kg for 4 days) (n=15). c. Mice with BCR-ABL-T315I induced CML were treated 
with a placebo (n=5) or omacetaxine (0.5 mg/kg, 4 days) (n=5), respectively, for 4 days 
beginning at day 10 after transplantation. Bone marrow cells were isolated from the 
treated CML mice, and leukemia stem cells were analyzed by FACS. The numbers of 
cells represents the average number of leukemia stem cells from the femur and tibia of 
each treated CML mouse. 
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Figure 3: Omacetaxine improves survival of mice with BCR-ABL-T315I-induced 
CML. 
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2.3.4 Omacetaxine caused degradation of BCR-ABL protein through inhibiting 
Hsp90 and reduced Mcl-1 protein level in myeloid leukemic cells. 
To understand the possible mechanisms by which omacetaxine inhibits myeloid 
leukemia cells, we examined the effect of omacetaxine on human myeloid leukemia 
cells (K562). In a dose-dependent manner, treatment with omacetaxine significantly 
suppressed K562 cell growth particularly at concentrations of 200 nM or more 
(P<0.001) (Figure 4a). We then compared protein levels in K562 cells after treatment 
with either 50 nM or 150 nM omacetaxine. After treatment, levels of BCR-ABL 
protein were decreased in K562 cells in a dose dependent manner (Figure 4b). As 
BCR-ABL protein is associated with Hsp90 protein125, we next measured the Hsp90 
protein levels and found that the Hsp90 protein levels were also decreased after 
omacetaxine treatment (Figure 4b). However, Hsp70 which plays a positive role in 
BCR-ABL–mediated resistance to apoptosis was not changed after omacetaxine 
treatment (Figure 4b). Down regulation of Mcl-1, a member of the Bcl-2 family, is 
associated with a substantial decrease in viability of K562 cells, and reduced survival 
of imatinib-resistant K562 cells152. The level of Mcl-1 protein was also greatly reduced 
following treatment with 150 nM omacetaxine treatment (Figure 4b). 
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Figure 4: Omacetaxine degrades BCR-ABL by inhibiting HSP90 and suppresses 
MCL-1 in myeloid leukemia cells. 
a. Omacetaxine inhibited K562 cells in a dose dependent manner. The number of 
viable cells at the indicated drug concentrations was determined by trypan blue. b. 
Omacetaxine inhibited the expression of Hsp90, Abl and Mcl-1 in K562 cells. K562 
cells were treated with omacetaxine (50 nM, 150 nM) for 48 hours. Protein lysates 
were analyzed by Western blotting using antibodies indicated.  
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Figure 4: Omacetaxine degrades BCR-ABL by inhibiting HSP90 and suppresses 
MCL-1 in myeloid leukemia cells. 
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2.3.5 Omacetaxine improves survival of mice with BCR-ABL induced B-ALL 
In contrast to CML(Figure 1), the development of B-ALL induced by BCR-ABL is not 
significantly affected by TKIs such as imatinib and dasatinib152,153. To induce B-ALL 
in mice, BCR-ABL–transduced bone marrow cells from donor mice that were not 
pretreated with 5-FU were transplanted into BALB/c mice36,149. To determine whether 
omacetaxine was effective in treating B-ALL, we used the B-ALL model, where pre-B 
cells express the B220 and CD19 cell surface antigens, and phenotypically resemble de 
novo Ph+ B-ALL and lymphoid blast crisis of CML36,154. These mice were treated with 
a placebo, 0.5mg/kg or 1mg/kg omacetaxine daily starting at day 10. After 4 days of 
treatment, only 2% of cells in peripheral blood were GFP+ B- leukemia cells in the 
1mg/kg group, compared with 20% GFP+ B-leukemia cells in 0.5mg/kg group or 50% 
GFP+ B-leukemia cells in placebo group (P < 0.001, Figure 5a and 5b). After 10 days 
of treatment, less than 2% GFP+ B-leukemia cells were detected in both drug treatment 
groups (Figure 5a and 5b) (P <0.001). All placebo-treated recipients of BCR-ABL 
transduced bone marrow developed and died of B-ALL within 4 weeks after BMT 
(Figure 5c), and all B-ALL mice treated with omacetaxine survived.  
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Figure 5: Omacetaxine improves survival of mice with BCR-ABL-induced B-ALL 
a and b Flow cytometric evaluation of the B-lymphoid leukemic process. The B-
lymphoid leukemic cells (GFP+B220+) were measured after placebo or omacetaxine 
(0.5 mg/kg or 1 mg/kg, n=4) treatment of B-ALL mice 4 days or 10 days after 
treatment. c. Treatment with the omacetaxine prolonged survival of BCR-ABL induced 
B-ALL mice. Mice with BCR-ABL induced B-ALL were treated with placebo (n = 15) 
or omacetaxine (1 mg/kg/day) (n=15). 
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Figure 5: Omacetaxine improves survival of mice with BCR-ABL-induced B-ALL 
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2.3.6 Omacetaxine inhibits BCR-ABL expression without affecting Hsp90 in B-
lymphoid cells expressing BCR-ABL. 
We further investigated whether omacetaxine also affects the expression levels of 
BCR-ABL and Hsp90 proteins in lymphoid cells expressing BCR-ABL. Pre-B cells 
expressing BCR-ABL or BCR-ABL-T315I from omacetaxine-treated B-ALL mice 
showed a concentration dependent inhibition of cell proliferation in response to 
omacetaxine (Figure 6a). We then compared BCR-ABL protein levels between placebo 
and omacetaxine (50 nM or 150 nM) treatment groups. After the treatment, the level of 
wild type BCR-ABL protein was slightly lower in omacetaxine treated B-leukemia 
cells, but the level of BCR-ABL T315I protein was markedly decreased. However, 
unlike myeloid leukemia cells (Figure 4b), the level of Hsp90 protein did not change 
after omacetaxine treatment (Figure 6b). 
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Figure 6: Omacetaxine inhibits B-ALL cells by suppressing BCR-ABL without 
affecting HSP90. 
a. Omacetaxine inhibited pre-B cells expressing BCR-ABL or BCR-ABL-T315I 
associated with drug concentration. The number of viable cells at the indicated drug 
concentrations was determined by trypan blue. b. Omacetaxine inhibited the expression 
of Abl in pre-B cells expressing BCR-ABL or BCR-ABL-T315I. These pre-B cells 
were treated with omacetaxine (50 nM, 150 nM) for 48 hours. Protein lysates were 
analyzed by Western blotting using antibodies indicated.  
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Figure 6: Omacetaxine inhibits B-ALL cells by suppressing BCR-ABL without 
affecting HSP90. 
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2.4 Discussion 
The BCR-ABL positive leukemia stem cell is a major target for curative therapy of 
Ph+ leukemias145. Although current TKI based therapies have significant clinical 
efficacy in Ph+ leukemias, these agents do not effectively kill BCR-ABL positive 
leukemia stem cells and only rarely elicit long lasting complete cytogenetic remission 
after cessation of therapy 22,144.  This finding has led to investigation of therapeutics 
that selectively kill BCR-ABL positive leukemia stem cells as potential novel 
treatments of Ph+ leukemias 44,146.  Here we have shown in animal models of Ph+ 
CML and B-ALL that omacetaxine effectively targets BCR-ABL positive leukemia 
stem cells in vivo and confers a significant survival benefit for leukemic mice.  In 
contrast, previous work has shown that the TKI imatinib did not affect the numbers of 
stem cells found in the circulation or the bone marrow of mice with CML26. These 
findings raise the possibility that clinical efficacy of omacetaxine in CML (where it is 
currently in phase 2/3 trials) may be due, at least in part, to its inhibiting activity on 
leukemic stem cells.  
The appearance of mutations in the BCR-ABL oncoprotein is a major cause of failure 
with imatinib therapy of BCR-ABL positive leukemias 155. Whilst the second 
generation TKIs dasatinib and nolotinib, inhibit many imatinib resistant mutant BCR-
ABL proteins, cells expressing T315I mutant BCR-ABL are resistant to all 3 TKIs 
currently used to treat CML.  Ongoing clinical trials have found that omacetaxine has 
clinical efficacy in CML patients with T315I mutant BCR-ABL126. Here we have 
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shown that omacectaxine significantly prolonged survival in these mice and 
dramatically reduced the number of T315I BCR-ABL positive leukemic cells both in 
vivo and in vitro. These observations support the clinical use of omacetaxine in CML 
patients with TKI resistant disease mediated by the T315I mutant BCR-ABL.  
The mechanisms for omacetaxine inhibition of Ph+ leukemic stem cells are unclear. As 
omacetaxine is an inhibitor of protein synthesis, we hypothesized that the anti-
leukemic activity of omacetaxine may be due to the loss of anti-apoptotic proteins. We 
postulated that omacetaxine may induce apoptosis in BCR-ABL positive CML cells via 
three potential pathways: (a) by directly reducing the expression of BCR-ABL, (b) by 
reducing the expression levels of BCR-ABL stabilizing proteins (such as Hsp90), 
which will lead to the degradation of BCR-ABL, and (c) by reducing the expression of 
the short lived anti-apoptotic Bcl-2 family protein Mcl-1.  We investigated the effect of 
omacetaxine on the expression of BCR-ABL, Hsp90 and Mcl-1 proteins in CML 
derived K562 cells and found that omacetaxine treatment induces the loss of BCR-
ABL, Hsp90 and Mcl-1. These observations are consistent with the hypothesis that 
omacetaxine acts by directly or indirectly inhibiting the BCR-ABL, Mcl-1 and Hsp90 
pathways in BCR-ABL positive CML cells and raise the possibility that omacetaxine 
acts on CML leukemic stem cells via reduced levels of these proteins.  
Acute lymphocytic leukemia in adults is commonly caused by the expression of BCR-
ABL. In general, B-ALL tends to show different symptoms, compared with CML. 
Omacetaxine removed most GFP+ B220+ cells from the peripheral blood with less than 
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1% GFP+ B220+ cells still detected by FACS and prolonged the survival of B-ALL 
mice. However, there was no change in Hsp90 protein levels, although BCR-ABL 
protein level was greatly reduced by omacetaxine. In CML, treatment with 
omacetaxine reduced the level of both Hsp90 and BCR-ABL protein demonstrating a 
different role for omacetaxine in treating CML and B-ALL. These results are consistent 
with our previous observation that BCR-ABL utilizes different signaling pathway to 
induce CML and B-ALL 149. Omacetaxine also has potential for treating CML and Ph+ 
B-ALL resistant to TKIs 128. 
2.5 Materials and methods 
Cell lines 
Human K562 myeloid leukemia cell line was grown in RPMI 1640 medium containing 
10% FCS. To generate the BCR-ABL–expressing pre-B cell lines, bone marrow cells 
were transduced with the BCR-ABL-WT- or BCR-ABL-T315I-IRES-GFP-MSCV 
retrovirus, followed by transplantation into recipient mice. The BCR-ABL-expressing 
cells were isolated from the spleen of a mouse with BCR-ABL induced B-ALL, and 
pre-B leukemic cells were selected through GFP sorting by fluorescence-activated cell 
sorter (FACS). To generate the BCR-ABL–expressing 32D line, the cells were 
transduced with the BCR-ABL-WT- or BCR-ABL-T315I-IRES-GFP-MSCV retrovirus, 
and the BCR-ABL–expressing cells were selected by GFP sorting by FACS. 
Histology 
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The lungs from the placebo- or drug-treated mice were fixed in Bouin fixative (Fisher 
Scientific, Pittsburgh, PA) for 24 hours at room temperature, followed by an overnight 
rinse in water. Ten-µm sections were stained with hematoxylin and eosin (H&E) and 
observed by a model DMRE compound microscope (Leica, Heidelberg, Germany). All 
sections were imaged with a 2.5 x PH1 objective (NPLan, NA 0.25) and 10 x PH1 
objective (NPLan, NA 0.40). All images were imported into MetaMorph software 
(Molecular Devices, Downingtown, PA) as a series of tagged image files. All images 
were then constructed in Adobe Photoshop 7.0 (Adobe, San Jose, CA).  
Antibodies and Western blot analysis 
Antibodies against c-ABL, Hsp90, Hsp70, Mcl-1 and actin were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Protein lysates were prepared by lysing cells in 
radioimmunoprecipitation (RIPA) buffer, and immunoprecipitation and Western 
blotting were carried out as described previously. 
Bone marrow transduction/transplantation 
The retroviral vector MSCV-IRES-EGFP carrying the p210 BCR-ABL cDNA was used 
to make high-titer, helper-free, replication-defective ecotropic virus stock by transient 
transfection of 293T cells using the kat system as previously described. 6- to 10-week-
old wild-type BABL/c or C57BL/6 mice (The Jackson Laboratory, Bar Harbor, Maine, 
and U.S.A) were used for leukemogenesis experiments. Induction of CML and B-ALL 
was as previously described. Briefly, to model CML, bone marrow from 5-fluorouracil 
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(5-FU)-treated (200 mg/kg) donor mice was transduced twice with BCR-ABL retrovirus 
by cosedementation in the presence of IL-3, IL-6, and stem cell factor(SCF). To model 
B-ALL, bone marrow from non-5-FU-treated donors was transduced without cytokines. 
Wild-type recipient mice were prepared by 900 cGy (for BABL/c) or 1100 cGy (for 
C57BL/6) gamma irradiation and a dose of 0.5 x 106 (CML) or 1.0 x 106 (B-ALL) cells 
transplanted via tail vein injection. Diseased mice were analyzed by histopathological 
and biochemical analyses as described previously.  
Flow cytometry 
Hematopoietic cells were collected from peripheral blood and bone marrow of diseased 
mice, and red blood cells were lysed with NH4Cl red blood cell lysis buffer (pH 7.4). 
The cells were washed with PBS, and stained with B220-PE for B cells, Gr-1-APC for 
neutrophils, and Sca1-APC/c-kit-PE for hematopoietic stem cells. After staining, the 
cells were washed once with PBS and subjected to FACS analysis.  
Culture of leukemia stem cells 
Bone marrow cells isolated from CML mice were cultured in vitro in the presence of 
stemspan SFEM, SCF, IGF-2, TPO, heparin, and FGF as reported previously for 
culture of hematopoietic stem cells. 
Drug treatment  
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Omacetaxine (ChemGenex Pharmaceuticals, Inc, Menlo Park, CA) was dissolved in 
0.9% NaCl to a stock concentration of 1 mg/ml. Further dilutions were made to 
working concentrations using media or water. Imatinib was dissolved in water directly 
at a concentration of 10 mg/ml. The drugs were given by either oral gavage for the 
CML model or by I.P. route for the B-ALL model in a volume of <0.5 ml, once a day, 
at 0.5 mg or 1.0 mg per kilogram of body weight for omacetaxine and 100 mg per 
kilogram of body weight per dose of imatinib, beginning at 10 days after bone marrow 
transplantation. 
Statistical analysis  
Results are reported as mean ± SD. Differences were evaluated by t test or analysis of 
variance, and accepted as significance when P value is less than 0.05. 
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Supplementary Figure1: The structure of omacetaxine mepesuccinate. 
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Supplementary Figure2: Analysis of leukemic stem cells in vitro and in vivo. 
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Chapter III 
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid 
leukemia 
The work described in this chapter has been published (Chen Y, Hu Y, Zhang H, Peng C, 
Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid 
leukemia. Nature Genetics. 2009, 41(7):783-92) 
3.1 Abstract 
Targeting of cancer stem cells is believed to be essential for curative therapy of cancers, 
but supporting evidence is limited. Few selective target genes in cancer stem cells have 
been identified. Here we identify the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) as 
a critical regulator for leukemia stem cells (LSCs) in BCR-ABL-induced chronic myeloid 
leukemia (CML). In the absence of Alox5, BCR-ABL failed to induce CML in mice. This 
Alox5 deficiency caused impairment of the function of LSCs but not normal 
hematopoietic stem cells (HSCs) through affecting differentiation, cell division, and 
survival of long-term LSCs (LT-LSCs), consequently causing a depletion of LSCs and a 
failure of CML development. Treatment of CML mice with a 5-LO inhibitor also 
impaired the function of LSCs similarly by affecting LT-LSCs, and prolonged survival. 
These 4inhibition can completely inhibit the function of these stem cells.  
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3.2 Introduction 
Cancer stem cells in many types of hematologic malignancies and solid tumors are 
believed to be a cell population that is required for cancer initiation and must be targeted 
for effective treatment of the diseases45-50, however, the direct supporting evidence is still 
lacking. The challenge includes identification of differences between cancer stem cells 
and their normal stem cell counterparts, and demonstration of complete control of cancer 
by targeting these stem cells. Success of an anti-stem cell strategy relies on complete 
inhibition of function of a gene required for maintenance of cancer stem cells but not 
normal stem cells. A number of genes have been found to promote or inhibit cancer cell 
proliferation, but they also play similar roles in regulating normal stem cells. Examples 
include pathways involved in signaling through Wnt/β-catenin, Hedgehog and 
Notch47,48,61,64,156,157, and Bim-1158,159, p53156, p16 INK4a160, etc. The role of Pten in 
inhibition of cancer stem cells of acute myeloid leukemia (AML) and in the maintenance 
of normal HSCs is unique, and provides an example that distinguishes AML stem cells 
from normal HSCs, although Pten has an effect on normal HSCs 161. Because cancer stem 
cells express markers similar to those on normal stem cells52,53, the major difference 
between them should be related to the cancer-initiating genetic changes such as acquiring 
an oncogene or accumulating a DNA mutation. It is reasonable to hypothesize that these 
genetic changes cause aberrant expression of genes, consequently turning a normal stem 
cell into a cancer stem cell. It is essential to identify genes that are functionally required 
by cancer stem cells but not by normal stem cell counterparts. Some clues for identifying 
genes that play roles in cancer stem cells could come from studies of normal stem cell 
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counterparts and different lineages of cancer cells80,162-164. It is reasonable to think that 
biological features of cancer stem cells are reflected by the deference in gene expression 
between cancer and normal stem cells. The list of aberrantly expressed genes could be 
huge, and it is critical to identify key genes or pathways that are required for initiating 
and maintaining cancer stem cells and can be used as targets for inhibiting these cells.  
We have tested our hypothesis using BCR-ABL-induced CML as a disease model 
system, as CML is a stem cell disease and we have previously identified LSCs for CML 
in mice26. In addition, CML stem cells are insensitive to BCR-ABL kinase inhibitors25,165. 
Here we identify Alox5 as a key gene that regulates the function of LSCs but not normal 
HSCs in mice. Alox5 has been shown to be involved in numerous physiological and 
pathological processes, including oxidative stress response, inflammation, and cancer 82-89. 
Here we also show that Alox5 deficiency or inhibition of function of this gene completely 
prevent the initiation of BCR-ABL-induced CML. 
3.3 Results 
3.3.1 Alox5 is essential for CML induction by BCR-ABL  
LSCs in CML are insensitive to BCR-ABL kinase inhibitors25. To identify genes that are 
regulated by BCR-ABL in LSCs, we used the bone marrow transplantation (BMT) mouse 
model of CML as an assay system, in which bone marrow cells from donor mice pre-
treated with 5-fluorouracil (5-FU) and transduced with BCR-ABL result in development 
of CML in recipient mice36. We transduced bone marrow cells from C57BL/6 (B6) mice 
with retrovirus containing BCR-ABL/GFP or GFP alone under conditions for induction 
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of CML, followed by transplantation of the transduced cells into B6 recipient mice. Some 
mice were treated with the BCR-ABL kinase inhibitor imatinib to allow identification of 
genes that were altered by BCR-ABL in LSCs, but this alteration was not restored by 
inhibition of BCR-ABL kinase activity with imatinib. This approach to identifying 
pathways that are activated by BCR-ABL but are insensitive to inhibition by imatinib is 
based on our previous observation that BCR-ABL kinase activity does not relate to all 
signaling pathways activated by BCR-ABL26. 14 days after BMT, bone marrow cells 
were isolated and subsequently sorted by FACS for LSCs (GFP+Lin-c-Kit+Sca-1+) 26. 
Total RNA was isolated from these BCR-ABL-expressing LSCs or from the GFP+Lin-c-
Kit+Sca-1+ cells that only expressed GFP, and DNA microarray analysis was carried out 
to compare gene expression between BCR-ABL-expressing and non-BCR-ABL-
expressing Lin-c-Kit+Sca-1+ cells. The Alox5 gene was up-regulated and this up-
regulation was not abolished by imatinib treatment (Figure 1a). There were several genes 
that were also up-regulated by BCR-ABL and not changed in expression following 
imatinib treatment (Supplementary Figure 1). The up-regulation of Alox5 by BCR-ABL 
in LSCs was confirmed by RT-PCR (Figure 1b). To further support the regulation of 
Alox5 by BCR-ABL, we tested whether BCR-ABL up-regulates Alox5 function by 
measuring levels of leukotriene B4 (LTB4), which is synthesized and metabolized 
through the 5-LO pathway, in peripheral blood of the transplanted mice. Plasma level of 
LTB4 was increased in CML mice (Figure 1c) 
 Next, we studied to study the role of Alox5 in regulation of LSC function using 
Alox5 homozygous knockout (Alox5-/-) mice. Wild type or Alox5-/- donor bone marrow 
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cells in B6 background were used to induce CML. We first investigated whether Alox5 is 
required for CML induction by BCR-ABL. Recipients of BCR-ABL-transduced bone 
marrow cells from 5-FU-treated wild type donor mice developed and died of CML within 
4 weeks, whereas recipients of BCR-ABL-transduced bone marrow cells from Alox5-/- 
donor mice were resistant to induction of CML (Figure 1d). This defective disease 
phenotype correlated with much less severe infiltration of myeloid leukemia cells in the 
lung and spleen (Figures. 1e, f). In addition, FACS analysis of CML cells in peripheral 
blood and bone marrow showed that Gr-1+ myeloid leukemia cells grew initially, reached 
a peak after 2 weeks, then started to decline, and eventually disappeared after 7 weeks in 
peripheral blood and bone marrow of recipients receiving BCR-ABL-transduced Alox5-/- 
donor bone marrow cells (Figures. 1 g, h). Alox5 deficiency mainly affected growth of 
BCR-ABL-expressing (GFP+) but not non-BCR-ABL-expressing (GFP-) donor bone 
marrow cells (Figure 1h), suggesting that Alox5 signaling is much more critical for 
function of LSCs but not normal HSCs. Together, these results demonstrate that Alox5 is 
essential for induction of CML by BCR-ABL.   
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Figure 1. Alox5 is essential for the induction of CML induced by BCR-ABL.  
a. Bone marrow cells from C57BL/6 mice (B6) were transduced with retrovirus containing BCR-
ABL/GFP or GFP alone (BCR-ABL-IRES-GFP-pMSCV or IRES-GFP-pMSCV), and then 
transferred into B6 recipient mice to induce CML. One group of CML mice was treated with 
imatinib (150 mg/kg body weight/ per dose, once every 4 hours) for 5 doses beginning at day 13 
post bone marrow transplantation (BMT). Bone marrow cells were isolated from CML mice, and 
were sorted by FACS for GFP+Lin-c-Kit+Sca-1+ cells (normal or CML stem cells). Total RNA 
was isolated from these sorted cells for DNA micorarray analysis. Expression of the Alox5 gene 
was up-regulated by BCR-ABL in CML stem cells as compared to the sorted GFP+Lin-c-Kit+Sca-
1+ cells that did not express BCR-ABL, and this up-regulation was not prevented by imatinib 
treatment. b. Bone marrow cells from C57BL/6 mice (B6) were transduced with retrovirus 
containing BCR-ABL/GFP or GFP alone to induce CML as described in a. Bone marrow cells 
were isolated from the mice were sorted by FACS for GFP+Lin-c-Kit+Sca-1+ cells, and then total 
RNA was isolated from these sorted cells for comparing Alox5 expression between GFP vector-
transduced normal stem cells and BCR-ABL-transduced LSCs by RT-PCR. Expression of the 
Alox5 gene was significantly up-regulated by BCR-ABL in LSCs as compared to the sorted GFP 
vector-transduced normal stem cells (p< 0.001). c. The plasma level of LTB4 in recipients of 
BCR-ABL-transduced bone marrow cells was significantly higher than that in recipients of bone 
marrow cells transduced with GFP-containing retrovirus (p< 0.05), and this increased level of 
LTB4 was not observed in recipients of Alox5-/- bone marrow cells transduced by BCR-ABL. 
These results indicated that BCR-ABL up-regulates LTB4 through Alox5. d. Kaplan-Meier 
survival curves for recipients of BCR-ABL-transduced bone marrow cells from wild type or 
Alox5-/- donor mice (10 mice per group).  All recipients of BCR-ABL-transduced bone marrow 
cells from wild type donor mice developed CML and died within 4 weeks after bone marrow 
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transplantation (days post BMT), whereas recipients of BCR-ABL-transduced bone marrow cells 
from Alox5-/- donor mice survived. e. Gross appearance of the lungs and spleens showed severe 
lung hemorrhages and splenomegaly of recipients of BCR-ABL-transduced bone marrow cells 
from wild type but not Alox5-/- donor mice. f. Photomicrographs of haematoxylin and eosin-
stained lung and spleen sections from recipients of BCR-ABL-transduced bone marrow cells from 
wild type or Alox5-/- donor mice. g. FACS analysis showed gradual disappearance of GFP+Gr-1+ 
cells in peripheral blood (PB) and bone marrow (BM) of recipients of BCR-ABL-transduced bone 
marrow cells from Alox5-/- but not wild type donor mice. h. In recipients of BCR-ABL-transduced 
bone marrow cells from Alox5-/- donor mice, GFP+Gr-1+ cells in PB gradually decreased with 
time, whereas the GFP-Gr-1+ cells that did not express BCR-ABL gradually increased, showing 
that Alox5 deficiency significantly inhibited engraftment of BCR-ABL-expressing but not normal 
BM cells in the same animals. Mean percentage for each group (n=5) was shown. 
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Figure 1. Alox5 is essential for the induction of CML induced by BCR-ABL.   
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3.3.2 Alox5 transgene rescues defective CML 
To further confirm the role of Alox5 in CML development, we co-expressed BCR-ABL 
and Alox5 in Alox5-/- and wild type bone marrow cells, respectively, by retroviral 
transduction, followed by transplantation of the transduced cells into recipient mice. The 
BCR-ABL-IRES-Alox5-pMSCV construct expressed BCR-ABL and 5-LO in 293T cells 
(Figure 2a), and induced LTB4 production in mice (Figure 2b). In contrast to no CML 
induction by BCR-ABL in the absence of Alox5 (Figure 1), ectopically expressed Alox5 
in Alox5-/- bone marrow cells rescued defective CML phenotype, and all mice receiving 
the BCR-ABL-IRES-Alox5-pMSCV transduced Alox5-/- bone marrow cells died (Figure 
2c). In this experiment, we included the control mice that received BCR-ABL transduced 
Alox5-/- bone marrow cells as shown in Figure1, and all these mice survived (data not 
shown). FACS analysis (Figure 2d) and peripheral blood smears (Figure2e) showed the 
development of typical CML after the expression of the rescue gene Alox5, consistent 
with the severe infiltration of myeloid leukemia cells in the lung and spleen (Figure 2f). 
The mice receiving the BCR-ABL-IRES-Alox5-pMSCV transduced wild type bone 
marrow cells died faster than those receiving the BCR-ABL-IRES-Alox5-pMSCV 
transduced Alox5-/- bone marrow cells (Figure 2c), correlating with more myeloid cells in 
peripheral blood (Figure 2d, e) and more severe infiltration of myeloid leukemia cells in 
the lung and spleen (Figure 2f). The results from this rescue experiment definitively 
confirmed that Alox5 plays a critical role in CML development. 
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Figure 2. Alox5 transgene rescues defective CML phenotype. a. The rescue construct 
(BCR-ABL-IRES-Alox5-pMSCV) was used to transfect 293T cells to test for expression 
of 5-LO with mock- or BCR-ABL-IRES-GFP-pMSCV-transfected cells as controls. 
BCR-ABL and 5-LO were detected by Western blotting using antibodies against Abl and 
5-LO. 5-LO protein was detected in cells transfected with BCR-ABL-IRES-Alox5-
pMSCV. b. Bone marrow cells from B6 mice were transduced with retrovirus containing 
IRES-GFP-pMSCV (empty vector) or BCR-ABL-IRES-Alox5-pMSCV, and then 
transferred into B6 recipient mice to induce CML. The plasma level of LTB4 in 
recipients of BCR-ABL-IRES-Alox5-pMSCV-transduced bone marrow cells was 
significantly higher than that in recipients of bone marrow cells transduced with empty 
vector-containing retrovirus (p< 0.01), confirming that the BCR-ABL-IRES-Alox5-
pMSCV construct induced LTB4 production in mice. c. Kaplan-Meier survival curves for 
recipients of BCR-ABL-IRES-Alox5-pMSCV-transduced bone marrow cells from wild 
type (n=10) or Alox5-/- (n=9) donor mice.  All recipient mice died. d. FACS analysis 
showed appearance of GFP+Gr-1+ cells in peripheral blood of recipients of BCR-ABL-
IRES-Alox5-pMSCV-transduced bone marrow cells from both wild type and Alox5-/- 
donor mice. e. Peripheral blood smears showed accumulation of neutrophils, indicating 
high white blood cell counts in these CML mice. f. Photomicrographs of haematoxylin 
and eosin-stained lung and spleen sections from recipients of BCR-ABL-IRES-Alox5-
pMSCV-transduced bone marrow cells from wild type or Alox5-/- donor mice.  
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Figure 2. Alox5 transgene rescues defective CML phenotype.                          
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3.3.3 Alox5 deficiency impairs the function of LSCs 
The eventual disappearance of myeloid leukemia cells in CML mice in the absence of 
Alox5 (Figure 1h) prompted us to examine whether Alox5 is required for self-renewal of 
LSCs. A biological assay for LSCs is to examine their ability to transfer disease to 
secondary recipient mice52,53. We transferred bone marrow cells from primary recipients 
of BCR-ABL-transduced wild type or Alox5-/- donor bone marrow cells to secondary 
recipient mice. BCR-ABL-expressing wild type bone marrow cells transferred lethal CML, 
whereas BCR-ABL-expressing Alox5-/- bone marrow cells failed to induce CML in 
secondary recipient mice (Supplementary Figure 2). This result suggests that Alox5 
deficiency causes the impairment of the function of LSCs.  
 The impaired CML development from LSCs in the absence of Alox5 could be 
caused by decreased number of LSCs. To test this hypothesis, we quantified LSCs 
(GFP+Lin-c-Kit+Sca-1+) and normal hematopoietic stem cells (HSCs) (GFP-Lin-c-
Kit+Sca-1+) in bone marrow and the spleens of CML mice at day 14 and day 18 after 
induction of CML. At day 14, Alox5 deficiency did not cause a reduction of LSCs in bone 
marrow and the spleens, but did so in bone marrow but not in the spleens at day 18, as 
compared to LSCs in wild type CML mice (Figure 3a); in the spleen, the number of 
Alox5-/- LSCs was similar to that of wild type LSCs (Figure 3a), indicating that the 
reduction of LSCs in bone marrow was not due to the migration of bone marrow LSCs to 
the spleens but due to an intrinsic defect caused by Alox5 deficiency in LSCs. Alox5 
deficiency did not cause a significant reduction of normal HSCs (GFP-) in bone marrow 
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and the spleens of the same animals (Figure 3a), suggesting that Alox5 is functionally 
required by LSCs but not by normal HSCs. In addition, we did not observe a homing 
defect of HSCs lacking Alox5 (Supplementary Figure 3), which could cause the impaired 
CML development when the cells were transduced by BCR-ABL (Figure 1). Furthermore, 
Alox5 deficiency did not appear to cause a homing defect on LSCs, as the total number of 
Alox5-/- LSCs was not lower than that of wild type LSCs at day 14 after induction of 
CML (Figure 3a).  
 Engraftment of donor bone marrow cells in lethally irradiated recipient mice 
reflects stem cell function. Alox5 deficiency could cause a decreased engraftment of 
LSCs, leading to a decrease in LSCs. To test this idea, LSCs were sorted by FACS from 
bone marrow of CML induced by transplanting BCR-ABL-transduced wild type (CD45.1) 
or Alox5-/- (CD45.2) donor bone marrow cells. Wild type and Alox5-/- LSCs were 1:1 
mixed, followed by transplantation into lethally irradiated recipient mice. At day 14 or 25 
after transplantation, more than 70% or 90% of GFP+Gr-1+ cells in peripheral blood of 
the mice were wild type (CD45.1+) leukemia cells, and all these mice developed CML 
and died (Figure 3b). Total wild type and Alox5-/- bone marrow cells were also 1:1 mixed, 
followed by transplantation into lethally irradiated recipient mice. At 40 day after BMT, 
more than 80% of GFP+Gr-1+ cells in peripheral blood were wild type (CD45.1+) 
leukemia cells, and all these mice died of CML (Supplementary Figure4). To further 
compare biological function between wild type and Alox5-/- LSCs, BCR-ABL-transduced 
wild type or Alox5-/- bone marrow cells were sorted by FACS for Lin-c-Kit+Sca-1+ cells, 
and equal number of the sorted wild type or Alox5-/- cells was transplanted into each 
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lethally irradiated recipient mouse. At day 14 after transplantation, GFP+Gr-1+ cells were 
detected in peripheral blood of recipient mice receiving BCR-ABL-transduced wild type 
but not Alox5-/- bone marrow donor cells (Figure 3c). By day 50 after transplantation, all 
mice receiving BCR-ABL-transduced sorted wild type bone marrow cells died of CML, 
whereas all mice receiving sorted Alox5-/- bone marrow cells survived (Figure 3c). These 
results indicated that Alox5 deficiency caused impairment of the function of LSCs, 
consequently leading to reduced production of leukemia progenitor cells. This conclusion 
is consistent with our finding that at day 20 after induction of CML, similar numbers of 
GFP+ CMP (common myeloid progenitor), GMP (granulocyte-macrophage progenitor), 
and MEP (megakaryocyte-erythroid progenitor) cells were detected in bone marrow of 
mice receiving BCR-ABL-transduced Alox5-/- donor bone marrow cells (Figure 3d); 
however, at day 45 these cells were much less in bone marrow of mice receiving BCR-
ABL transduced Alox5-/- donor marrow cells (Figure 3d). By contrast, Alox5-/- deficiency 
did not cause reduction of non-BCR-ABL-expressing myeloid progenitor cells in the 
same animals (Figure 3d), providing an indirect evidence that Alox5-/- deficiency only 
causes a functional defect in LSCs but not normal HSCs. This conclusion was further 
confirmed by comparing the engraftment of wild type (CD45.1) and Alox5-/- (CD45.2) 
bone marrow cells by injecting the same number of each type of bone marrow cells into 
lethally irradiated recipient mice. At 30 day after BMT, the percentage of wild type or 
Alox5-/- bone marrow cells was similar (Supplementary Figure 5). A control experiment 
showed that after lethal irradiation, 100 % of cells in peripheral blood of recipient mice 
were donor-derived when assayed at day 30 after BMT (data not shown), allowing the 
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direct analysis of CD45.1 or CD45.2 cells to reflect the donor-derived wild type (CD45.1) 
and Alox5-/- (CD45.2) bone marrow cells in the same animal. 
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Figure 3. Loss of Alox5 impairs the function of CML stem cell. a. BCR-ABL-
expressing (GFP+) and non-BCR-ABL-expressing (GFP-) Lin-c-Kit+Sca-1+ cells (CML 
stem cells) in BM and the spleens (SPL) were analyzed by FACS in recipients of BCR-
ABL-transduced BM cells from wild type or Alox5-/- donor mice (n=4 for each group at 
two time points after BMT). Total number of Lin-c-Kit+Sca-1+ cells for each mouse was 
calculated as percentage of Lin-c-Kit+Sca-1+ cells x total cell count for the cells from 
femurs and tabias. Loss of Alox5 caused significant reduction of CML stem cells in BM 
(p< 0.05). b.  Equal numbers of the sorted Lin-c-Kit+Sca-1+ cells from recipients of BCR-
ABL-transduced bone marrow cells from wild type (CD45.1) or Alox5-/-(CD45.2) donor 
mice were mixed, followed by transplantation into lethally irradiated wild type mice. At 
days 14 and 25 after BMT, FACS analysis showed that the percentages of CD45.1+ cells 
were much higher than those of CD45.2+ cells. All these mice died of CML, presumably 
due to the development of CML from CD45.1+ cells. c. Lin-c-kit+Sca-1+ cells sorted by 
FACS from BCR-ABL-transduced BM cells from wild type or Alox5-/- mice were injected 
into lethally irradiated wild type recipient mice (15000 Lin-c-kit+Sca-1+ cells per recipient 
mouse). At day 14 after BMT, GFP+ Gr-1+ cells in peripheral blood of the mice were 
analyzed by FACS. Alox5-deficient Lin-c-kit+Sca-1+ poorly engrafted. The mice receiving 
the Alox5-deficient Lin-c-kit+Sca-1+ cells survived (n=4), whereas the mice receiving the 
wild type Lin-c-kit+Sca-1+ cells died of CML (n=2). d. FACS analysis indicated the 
percentages of BCR-ABL-expressing (GFP+) and non-BCR-ABL-expressing (GFP-) 
CMP, GMP, and MEP cells in BM of recipients of BCR-ABL-transduced wild type or 
Alox5-/- donor BM cells (n=4). The results showed that loss of Alox5 caused depletion of 
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BCR-ABL-expressing but not non-BCR-ABL-expressing CMP, GMP, and MEP cells in 
BM of the mice. 
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Figure 3. Loss of Alox5 impairs the function of CML stem cell.                        
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3.3.4 Alox5 deficiency affects differentiation, cell division and survival of LT-LSCs 
Alox5 deficiency caused the impairment of function of LSCs (Figure 3), and these cells 
were phenotypically Lin-c-Kit+Sca-1+, including long-term (LT) HSCs, short-term (ST) 
HSCs, and multipotent progenitor (MPP) cells. We further investigated which of these 
cell populations is affected by Alox5 deficiency. BCR-ABL-transduced Alox5-/- bone 
marrow cells were transplanted into recipient mice to induce CML, and bone marrow 
cells from these mice were analyzed by FACS for percentages of total HSCs (Lin-c-
Kit+Sca-1+), LT-HSCs (Lin-c-Kit+Sca-1+CD34-), and ST-HSCs /MPP cells (Lin-c-
Kit+Sca-1+CD34+). At day 20 after induction of CML, the percentage or total number of 
bone marrow LT-LSCs (GFP+Lin-c-Kit+Sca-1+CD34-) was about 1/2 of those of ST-
LSCs/MPP cells (GFP+Lin-c-Kit+Sca-1+CD34+) (Figure 4a). However, at day 90, the 
percentage or total number of LT-LSCs was about 8 fold higher than that of ST-
LSCs/MPP cells (Figure 4a). These results suggest that Alox5 deficiency blocks 
differentiation of LT-LSCs, preventing these cells from developing CML. In these mice, 
the percentage of GFP- LT-HSCs was much lower than that of GFP- ST-HSCs/MPP cells 
(Supplementary Figure 6), demonstrating that Alox5 deficiency does not similarly affect 
differentiation of normal LT-HSCs. Although loss of Alox5 caused a relative high 
percentage of LT-LSCs than that of ST-LSCs/MPP cells, the total number of LT-LSCs 
declined with time (Figure 4a), suggesting that Alox5 deficiency caused a gradual 
depletion of LSCs. 
 The effect of Alox5 deficiency on LSCs was further demonstrated in experiments 
showing that Alox5 function was inhibited by a selective 5-LO inhibitor Zileuton166. 
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BCR-ABL-transduced wild type bone marrow cells were transplanted into recipient mice 
to induce CML, and LSCs in bone marrow cells of these mice treated with Zileuton (300 
mg/kg of body weight, twice a day) were analyzed by FACS at days 20 and 90 after 
induction of CML. As the treatment went on, the ratio between the percentage of LT-
LSCs and that of ST-LSCs/MPP cells became increasing (Figure 4b), suggesting a 
blockade of differentiation of LT-LSCs. Zileuton treatment did not similarly affect 
differentiation of GFP- LT-HSCs in the same animals (Figure 4b), suggesting that 
inhibition of 5-LO does not suppress normal HSCs. These findings were consistent with 
those from the studies using Alox5-/- mice (Figure 4a). No suppression of normal HSCs 
was further demonstrated in placebo- or Zileuton-treated mice receiving wild type donor 
bone marrow cells transduced with MSCV-IRES-GFP retrovirus. At day 14 after BMT, 
the numbers of GFP+Lin-c-Kit+Sca-1+ cells in bone marrow of placebo- and Zileuton-
treated mice were compared. Zileuton treatment did not result in a reduction of GFP+Lin-
c-Kit+Sca-1+ cells in bone marrow and the spleens of the mice (Figure 4c). 
 The blockade of LT-LSC differentiation was correlated with biological and 
molecular changes in LSCs. Cell cycle analysis of LSCs in bone marrow of CML mice 
showed that there was higher percentage of LT-LSCs in the S+G2M phase of the cell 
cycle in mice receiving BCR-ABL-transduced Alox5-/- bone marrow cells than in mice 
receiving BCR-ABL-transduced wild type bone marrow cells (Figure 4d); however, the 
percentages of LT-LSCs and ST-LSCs/MPPs in the S+G2M phase of the cell cycle were 
similar (Figure 4d), suggesting that this differentiation blockade caused a compensatory 
response of Alox5 deficient LSCs to the shortage of downstream cell lineages. The higher 
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percentage of LT-LSCs in the S+G2M phase of the cell cycle in the absence of Alox5 
may also be explained by asymmetric cell division of LT-LSCs. Alox5 deficiency also 
caused slightly increased apoptosis of LSCs (p> 0.05) (Figure 4e), but the apoptotic ratio 
between Alox5-/- ST-LSCs/MPPs and LT-LSCs was similar to the ratio between Alox5+/+ 
ST-LSCs/MPPs and LT-LSCs (Supplementary Figure 7). To study the underlying 
mechanism for the defective function of LSCs at molecular level, we examined the 
expressive levels of three regulatory genes of hematopoiesis, β-catenin, GATA-1 and 
FOG-161,167,168. We found that the defective function of LSCs in the absence of Alox5 was 
correlated with the reduction of β-catenin and GATA-1 but not FOG-1 (Figure 4f).  
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Figure 4. Loss of Alox5 function blocks differentiation of LT-LSCs.  
a. Bone marrow cells were isolated from recipients of BCR-ABL-transduced bone marrow 
cells from wild type or Alox5-/-donor mice, and FACS analysis showed that the 
percentages and total numbers of LT-LSCs (GFP+Lin-c-Kit+Sca-1+CD34-) and ST-LSCs 
/BCR-ABL-expressing MPP cells (Lin-c-Kit+Sca-1+CD34+) in recipients of BCR-ABL-
transduced Alox5-/- (middle and right panels) donor BM cells were much lower than those 
in recipients of BCR-ABL-transduced wild type (left panel) donor BM cells (n=4). In 
addition, LT-LSCs in recipients of BCR-ABL-transduced Alox5-/- donor BM cells 
relatively accumulated due to the blockade of differentiation, resulting in depletion of 
ST-LSCs /BCR-ABL-expressing MPP cells as assayed at day 90 post BMT. b. Recipients 
of BCR-ABL-transduced bone marrow cells from wild type donor mice were treated with 
Zileuton (300 mg/kg, twice a day) beginning at 8 days after BMT. At days 20 and 90 post 
BMT, FACS analysis showed the depletion of ST-LSCs /BCR-ABL-expressing MPP 
cells in Zileuton-treated CML mice, indicating a blockade of differentiation of LT-LSCs. 
In contrast, in the same animals the percentages and total numbers of ST-HSCs /MPP 
cells were higher than those of LT-LSCs, indicating that Zileuton treatment did not lead 
to a blockade of differentiation of normal LT-HSCs in Zileuton-treated CML mice. c. 
Mice receiving wild type donor BM cells transduced with MSCV-IRES-GFP retrovirus 
were treated with a placebo or Zileuton as described in b. At day 14 after BMT, the 
numbers of GFP+Lin-c-Kit+Sca-1+ cells in BM and the spleens (SPL) of placebo- and 
Zileuton-treated mice were compared. Zileuton treatment did not result in a reduction of 
normal HSCs in the mice. d. At day 14 after BMT, bone marrow cells were isolated from 
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recipients of BCR-ABL-transduced bone marrow cells from wild type or Alox5-/-donor 
mice. The cells were stained with Hoechst Blue, and DNA contents, represented by the 
percentages of three LSC populations (total LSCs, LT-LSCs, and ST-LSCs+MPPs) in the 
S+G2M phase of the cell cycle, was examined by FACS. Mean percentage for each cell 
population (n=5) was shown. e. At day 14 after BMT, bone marrow cells were isolated 
from recipients of BCR-ABL-transduced bone marrow cells from wild type or Alox5-/-
donor mice. The cells were stained with PI and Hoechst Blue, and the percentages of 
LSCs positive for PI and Hoechst Blue, representing apoptotic cells, were determined by 
F ACS. f. Bone marrow GFP+Lin-c-Kit+Sca-1+ cells were sorted by FACS from recipients 
of GFP vector- or BCR-ABL-transduced bone marrow cells from wild type or Alox5-/- 
donor mice for isolation of total RNA, and expression of β-catenin, GATA-1 and FOG 
were detected by RT-PCR. Each bar represents the mean value of three samples. BMCs: 
bone marrow cells. 
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Figure 4. Loss of Alox5 function blocks differentiation of LT-LSCs.                
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3.3.5 Inhibition of 5-LO prolongs survival of CML mice 
Zileuton treatment suppressed LSCs in CML mice (Figure 4). We examined whether 5-
LO serves as a potential target in LSCs for treating CML. Mice with BCR-ABL-induced 
CML were treated with a placebo, the 5-LO inhibitor Zileuton, imatinib alone, or two 
agents in combination. All placebo-treated mice developed and died of CML within 4 
weeks after induction of CML. Zileuton inhibited Alox5 function in CML mice, as 
plasma level of LTB4 was decreased compared to placebo-treated CML mice (Figure 5a). 
As expected, imatinib treatment was effective in treating CML, but Zileuton treatment 
was even more effective (Figure 5b). Treatment of CML mice with both Zileuton and 
imatinib had a better therapeutic effect than with either Zileuton or imatinib alone in 
prolonging survival of the mice (Figure 5b). Prolonged survival of Zileuton-treated CML 
mice correlated with less severe leukemia cell infiltration to the lungs and the spleens 
(Figure 5c). In peripheral blood of CML mice treated with Zileuton and imatinib, 
GFP+Gr-1+ leukemia cells gradually decreased with treatment, and dropped from over 50% 
to less than 2%, as analyzed at day 60 after induction of CML (Figure 5d). Although 
these mice eventually died (Figure 5d), FACS analysis barely detected any GFP+Gr-1+ 
myeloid leukemic cells in peripheral blood (data not shown), indicating that myeloid 
leukemia was eliminated. Instead, these mice developed ALL, as shown by the presence 
of GFP+B220+ leukemic cells in peripheral blood (data not shown).  Zileuton treatment 
did not have an inhibitory effect on normal myeloid cells (GFP-Gr-1+) in peripheral blood 
of the same animals, as the number of these non-leukemia cells increased during the 
treatment (Figure 5e). In bone marrow of Zileuton-treated CML mice, GFP+Gr-1+ 
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myeloid leukemia cells also dropped to low levels during the treatment (Figure 5f). 
Prolonged survival of CML mice by Zileuton treatment is consistent with the inhibitory 
effect of Zileuton on LSCs (Figure 4b). Zileuton treatment caused a reduction of white 
blood cell counts less dramatically than did imatinib treatment (Supplementary Figure 8), 
presumably because Zileuton targeted LSCs and imatinib inhibited more differentiated 
leukemic cells. Zileuton treatment also prolonged survival of mice with CML induced by 
BCR-ABL-T315I (Supplementary Figure 9). 
 Elevation of LTB4 level was observed in bone marrow cells of CML patients 169. 
However, a later report from the same group showed that the level of leukotriene C4 
(LTC4) synthase, which is a key enzyme in the biosynthesis of LTC4 and represents a 
different metabolic pathway from LTB4, was elevated in human CML cells. Therefore, 
we examined whether BCR-ABL stimulates LTC4 production in CML mice using an 
ELISA method. We did not observe an increase of plasma LTC4 levels in mice receiving 
BCR-ABL-expressing wild type bone marrow cells (BCR-ABL+Alox5+/+) as compared 
to mice receiving BCR-ABL-expressing Alox5 deficient bone marrow cells (BCR-
ABL+Alox5-/-). The mean level of LTC4 was 128.63 pg/ml for the BCR-ABL+Alox5+/+ 
group and 154.84 pg/ml for the BCR-ABL+Alox5-/- group, respectively. 
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Figure 5. Inhibition of Alox5 prolongs survival of CML mice. 
a. Zileuton treatment resulted in a reduction of the plasma LTB4 level in CML mice. b. 
Kaplan-Meier survival curves for CML mice treated with a placebo, Zileuton alone, 
imatinib alone, or both Zileuton and imatinib in combination. Zileuton-treated CML mice 
were much healthier than placebo-treated CML mice, and inhibition of Alox5 by Zileuton 
significantly prolonged survival of CML mice. c. Photomicrographs of haematoxylin and 
eosin-stained lung and spleen sections from CML mice treated with a placebo or Zileuton. 
d. FACS analysis showed gradual disappearance of GFP+Gr-1+ cells in PB of CML mice 
treated with Zileuton. e. In CML mice treated with Zileuton, GFP+Gr-1+ cells in PB 
gradually decreased with time, whereas the GFP-Gr-1+ cells that did not express BCR-
ABL gradually increased, showing that inhibition of Alox5 with Zileuton significantly 
inhibited engraftment of BCR-ABL-expressing but not normal BM cells in the same 
animals. f. FACS analysis showed gradual disappearance of GFP+Gr-1+ cells in BM of 
CML mice treated with Zileuton. 
 
 
 
 
97 
 
 
Figure 5. Inhibition of Alox5 prolongs survival of CML mice. 
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 3.3.6 Alox5 deficiency does not significantly affect normal HSCs 
Alox5 deficiency or inhibition of 5-LO by Zileuton specifically impaired the function of 
Alox5-/- LSCs but not non-BCR-ABL-expressing Alox5-/- HSCs in CML mice (Figures. 4, 
5), showing that these Alox5-/- HSCs had stronger stem cell ability to engraft recipient 
mice than did Alox5-/- LSCs in the same animals. However, these results did not clearly 
show whether Alox5 deficiency affected the function of normal HSCs. This question is 
important, because it is critical to know whether Alox5 deficiency or inhibition of 5-LO 
lowers the function of HSCs below their normal level, especially if Alox5 were 
considered as a therapeutic target. We characterized hematopoietic cell lineages in bone 
marrow and peripheral blood of Alox5-/- mice in comparison with those of wild type B6 
mice. The percentages of HSCs (Lin-c-Kit+Sca-1+), LT-HSCs (Lin-c-Kit+Sca-1+CD34-), 
ST-HSCs (Lin-c-Kit+Sca-1+CD34+Flt3-) and MPPs (Lin-c-Kit+Sca-1+CD34+Flt3+) in bone 
marrow of Alox5-/- mice were slightly lower than those of wild type mice (Figure 6a), and 
the percentages of Gr-1+, Mac-1+, B220+, or CD3E+ cell populations in bone marrow of 
these mice were similar to those of wild type mice (Figure 6b). In peripheral blood, Gr-1+ 
and Mac-1+ cells in Alox5-/- mice were even higher than those in wild type mice (Figure 
6b). These results demonstrated that Alox5 deficiency did not lead to significant decrease 
in the numbers of hematopoietic cell lineages. 
 To compare the function of HSCs between Alox5-/- and wild type mice, we first 
performed engraftment assay, in which several doses of Alox5-/- or wild type bone 
marrow cells were transplanted into lethally irradiated wild type B6 mice. The 
engraftment ability of Alox5-/- bone marrow cells was slightly lower than that of wild type 
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bone marrow cells, as 5x104 wild type bone marrow cells completely protected death of 
lethally irradiated recipient mice, whereas the same number of Alox5-/- bone marrow cells 
partially rescued the irradiated mice (Figure 6c). The minor engraftment defect of Alox5-/- 
bone marrow cells was further examined in a competitive reconstitution analysis, in 
which Alox5-/- (CD45.2) and wild type (CD45.1) bone marrow cells were 1:1 mixed and 
then transferred into recipient mice. 12 weeks after transplantation, the percentages of 
CD45.2 Gr-1+ and Mac-1+ cells were lower than those of CD45.1 Gr-1+ and Mac-1+ cells 
in peripheral blood (Figure 6d), indicating that Alox5-/- HSCs had slightly lower stem cell 
function as compared to wild type HSCs. However, the effect of Alox5 deficiency on 
normal HSCs is much less than that on LSCs, as the competitive engraftment capability 
of the sorted Alox5-/- LSCs was about thirty fold lower than that of wild type LSCs as 
assayed at day 25 after CML induction (Figure 3c), comparing to the one fold difference 
between Alox5-/- and normal HSCs (Figure 6d). This was further supported by the 
observation that Alox5-/- LSCs failed to induce CML (Figure 3c). We also compared the 
numbers of bone marrow CMP, GMP, MEP, and CLP between wild type and Alox5-/- 
mice, and no significant differences were found (Figure 6e), suggesting that there were 
no significant functional defects in these progenitor cells. The minor functional defect of 
Alox5-/- HSCs promoted us to examine whether there were any cellular changes in cell 
cycle and gene expression of β-catenin, GATA-1 and FOG-1 in these cells. We found 
that there were slightly higher percentages of both LT-HSCs and ST-HSCs/MPPs in the 
S+G2M phase of the cell cycle in Alox5-/- bone marrow cells than in wild type bone 
marrow cells (Figure 6f), in contrast to the only increase in LT-LSCs in S+G2M phase of 
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the cell cycle in BCR-ABL-expressing Alox5-/- bone marrow cells (Figure 4d). This 
further indicates that there is no differentiation blockade in Alox5-/- HSCs and that Alox5 
deficiency has distinct biological effect on normal HSCs and LSCs. To support this idea, 
we compared the expressive levels of β-catenin, GATA-1 and FOG-1 in HSCs of wild 
type and Alox5-/- mice. We found that the minor functional defect of Alox5-/- HSCs was 
correlated with a decreased expression of GATA-1 and FOG-1, and that β-catenin 
expression was increased in Alox5-/- HSCs compared to that in wild type HSCs (Figure 
6g). Different expression patterns of β-catenin, GATA-1 and FOG-1 in Alox5-/- HSCs 
(Figure 6g) and LSCs (Figure 4e) indicate that these three genes function differently in 
these two types of stem cells. 
 
 
 
 
 
 
 
 
 
101 
 
Figure 6. Alox5 deficiency does not significantly affect normal HSCs.  
a. Bone marrow cells from wild type and Alox5-/-mice were analyzed by FACS for the 
percentages of total HSCs (Lin-c-Kit+Sca-1+), LT-HSCs (Lin-c-Kit+Sca-1+CD34-), ST-
HSCs (Lin-c-Kit+Sca-1+CD34+Flt3-), and MPPs (Lin-c-Kit+Sca-1+CD34+Flt3+). b. Cells 
from bone marrow and peripheral blood of wild type and Alox5-/-mice were analyzed by 
FACS for the percentages of Gr-1+, Mac-1+, B220+, and CD3E+ cells. c. Three doses 
(1x105, 5x104, and 2.5x104) of wild type or Alox5-/-BM cells were injected into lethally 
irradiated recipient mice. Survival curves showed that there was only a minor 
engraftment defect of BM in Alox5-/-mice. d. Alox5-/- (CD45.2) and wild type (CD45.1) 
BM cells were 1:1 mixed and then transferred into recipient mice (n=20). 12 weeks after 
BMT, FACS analysis was carried out to compare the percentages of wild type and Alox5-
/-Gr-1+, Mac-1+, B220+, and CD3E+ cells in PB of recipient mice. e. BM cells from BM 
of wild type and Alox5-/-mice were analyzed by FACS for the numbers of CMPs, GMPs, 
MEP, and CLPs. f. Bone marrow cells were isolated from wild type or Alox5-/- mice, and 
stained with Hoechst Blue. DNA contents in total HSCs, LT-HSCs, and ST-HSCs+MPPs 
in the S+G2M phase of the cell cycle were examined by FACS. g. Bone marrow HSCs 
were sorted by FACS from wild type or Alox5-/- mice for isolation of total RNA, and 
expression of β-catenin, GATA-1 and FOG were detected by RT-PCR. Each bar 
represents the mean value of three samples. 
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Figure 6. Alox5 deficiency does not significantly affect normal HSCs.            
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3.3.7 Alox5 is not required for the induction of lymphoid leukemia by BCR-ABL 
We tested whether Alox5 plays a role in BCR-ABL-induced acute lymphoblastic 
leukemia (ALL), which originates from committed lymphoid progenitors 36. We have 
previously shown that BCR-ABL-expressing pro-B cells serve as LSCs for this disease 26. 
Wild type or Alox5-/- donor bone marrow cells in B6 background were transduced by 
BCR-ABL retrovirus followed by transplantation of the transduced cells into lethally 
irradiated wild type B6 recipient mice. Both groups of mice developed and died of ALL 
with similar disease latency and survival time (Figure 7a). FACS analysis of lymphoid 
leukemia cells in peripheral blood of these mice showed that both group of ALL mice 
had similar percentages (Figure 7b) and numbers (Figure 7c) of B220+ leukemia cells in 
peripheral blood. Together these results showed that Alox5 did not contribute to the 
development of ALL induced by BCR-ABL, and suggest that Alox5 is not required by 
ALL stem cells, but is specifically required by CML stem cells. Consistent with these 
findings, BCR-ABL did not up-regulate Alox5 function, as the plasma level of LTB4 in 
recipients of BCR-ABL-transduced wild type bone marrow cells was not significantly 
higher compared to recipients of BCR-ABL-transduced Alox5-/- bone marrow cells (Figure 
7d). 
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Figure 7. Alox5 is not required for the induction of lymphoid leukemia by BCR-ABL. 
 a. Kaplan-Meier survival curves for recipients of BCR-ABL-transduced bone marrow 
cells from wild type (n=6) or Alox5-/- (n=8) donor mice.  Both groups of mice developed 
and died of ALL. b. At day 14 post BMT, FACS analysis showed no difference in the 
percentages of GFP+B220+ cells in PB of recipients of BCR-ABL-transduced bone 
marrow cells from wild type or Alox5-/- donor mice. c. FACS analysis showed similar 
numbers of GFP+B220+ cells in PB of recipients of BCR-ABL-transduced bone marrow 
cells from wild type or Alox5-/- donor mice. d. The plasma levels of LTB4 in recipients of 
BCR-ABL-transduced bone marrow cells from wild type or Alox5-/- donor mice were 
compared.  Loss of Alox5 did not result in a reduction of the plasma LTB4 level in ALL 
mice. 
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Figure 7. Alox5 is not required for the induction of lymphoid leukemia by BCR-ABL. 
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3.4 Discussion 
The specific role of the Alox5 gene in regulating function of LSCs but not normal 
HSCs proposes a new mechanism for how cancer and normal stem cells distinctly self-
renew and differentiate, and provides a potential novel strategy for curative therapy of 
CML induced by BCR-ABL. Although Alox5 and its related pathways were identified in 
LSCs of CML, they may play a critical role in regulating LSCs of myeloid leukemias 
induced by other types of oncogenes. This idea is supported by our preliminary finding 
that the development of Tel-PDGFR-beta induced myeloid leukemia was also largely 
prevented in the absence of the Alox5 gene (data not shown). In addition, similar 
phenomenon that a gene specifically regulates cancer stem cells but not normal stem cells 
may likely be found in other types of cancers.  
The mechanism for the specific role of the Alox5 gene in regulating function of 
LSCs but not normal HSCs remains to be further elucidated. We showed the differential 
regulation of the beta-catenin gene in wild type and Alox5 deficient LSCs, partially 
explaining the specific inhibitory effect of Alox5 deficiency on LSCs but not on normal 
HSCs. It is reasonable to think that these two types of stem cells utilize different 
pathways for self-renewal and differentiation, and Alox5 represents a critical difference in 
these stem cells. It is likely that BCR-ABL stimulates transcription of Alox5 to jointly 
form a unique pathway critical for LSC function. Because the transcriptional activation of 
Alox5 by BCR-ABL is not inhibited by the BCR-ABL kinase inhibitor imatinib, this at 
least partially explains why imatinib does not inhibit LSCs in CML mice 26. It is hopeful 
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that targeting Alox5 in combination with a BCR-ABL inhibitor that eliminates BCR-ABL 
protein, such as a heat shock protein 90 inhibitor 125, would lead to a better control of 
CML. 5-LO inhibitor and imatinib could also be a good combination, with one inhibiting 
LSCs and another eliminating differentiated leukemia cells. 
No studies have shown a role of Alox5 in regulation of LSCs. Our findings in this 
study first demonstrate that Alox5 is a critical regulator of LSCs in CML, providing an in 
vivo system for investigating underlying molecular mechanisms. Human CML 
microarray studies have shown that Alox5 is differentially expressed in CD34+ CML cells 
28,29, suggesting a role of Alox5 in human CML stem cells. An in vitro study also supports 
the role of Alox5 in CML, and in this study the treatment of CML blast cells in culture 
with 5-LO inhibitors reduced cell proliferation 93, although genetic approach is required 
to rule out any off-target effects. Our study shows complete eradication of myeloid 
leukemia in mice by removing and inhibiting 5-LO, prompting us to test this novel 
therapeutic strategy in human CML patients. Alox5 function has been linked to many 
important signaling pathways such as p53 82, NF-kB 87, and PI3K 87 that is regulated by 
Pten, which has been shown to play a critical role in AML stem cells in mice 161. Thus, 
inhibition of Alox5 function may hold a promise for treating other types of malignant 
diseases. In addition, complete blockade of LSCs in CML development by inhibiting 
Alox5 function also suggests that Alox5 may activate unknown pathways, and 
investigation of this Alox5 network is critical to understand the mechanisms by which 
LSCs survive, self-renew, and differentiate. By DNA microarray analysis, we showed the 
differential expression of 50 genes regulated by Alox5, providing clues for further 
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elucidating the mechanisms by which Alox5 regulated LSC function. Besides LSCs in 
CML, specific signaling networks are likely found in other cancer stem cells, relative to 
their normal stem cell counterparts. 
3.5 Materials and Methods 
Mice. C57BL/6J-CD45.1, C57BL/6J-CD45.2, and homozygous Alox5 knockout (Alox5-/-) 
mice in C57BL/6 background were obtained from The Jackson Laboratory. Mice were 
maintained in a temperature- and humidity-controlled environment and given unrestricted 
access to 6% chow diet and acidified water. Alox5-/- mice have normal hematopoietic cell 
counts in bone marrow and peripheral blood83. 
Flow cytometry and identification of leukemia and normal hematopoietic cell 
lineages. Hematopoietic cells were collected from bone marrow and peripheral blood of 
the normal and diseased mice, and red blood cells were lysed with NH4Cl red blood cell 
lysis buffer (pH 7.4). The cells were washed with PBS, and stained with B220-PE for B 
cells, Gr-1-APC for neutrophils, Mac-1-PE for macrophage, CD3E-APC for T cells, and 
Sca-1-PE-cy7/c-Kit-APC-cy7/CD34-APC/CD135 (Flt3)-PE for hematopoietic stem cells. 
After staining, the cells were washed once with PBS and subjected to FACS analysis.  
Bone marrow transduction/transplantation. The retroviral vector MSCV-IRES-eGFP 
carrying the p210 BCR-ABL cDNA and retroviral transduction and transplantation of 
mouse bone marrow cells for induction of CML and ALL by BCR-ABL had been 
described previously125,149.  
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Measurement of plasma LTB4. Plasma of BCR-ABL induced CML mice were 
collected on day 20 post induction of the disease, and stored at the -80 oC before use. An 
enzyme immunoassay was carried out to measure the LTB4 levels in plasma using an 
ELISA kit (Cayman Chemical, Ann Arbor, MI) following the manufacturer’s instruction. 
Briefly, 50 ul of each standard or plasma sample was added to each well of 96-well plates, 
followed by adding 50 ul of LTB4 AchE trancer to each well. Then, 50 ul of LTB4 EIA 
antiserum was added to each well, and incubated the plates at 4 oC overnight. Next day, 
the plates were read and the results were analyzed. 
Western blot analysis and antibodies: Antibodies against c-ABL, β-actin, and 5-LO 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein lysates were 
prepared by lysing cells in RIPA buffer, and Western blotting was carried out as 
described previously 4. 
Real-time PCR. Total mRNA was isolated from HSCs or LSCs isolated by the FACS 
sorting. cDNA was synthesized using the Ovation-Pico cDNA synthesis method. Real-
time PCR (RT-PCR) was performed to detect expression of β-catenin, GATA-1 and 
FOG-1 with the following primers: β-catenin forward primer 
5’AACAGGGTGCTATTCCACGACTA-3’ and reverse primer 5’-
TGTGAACGTCCCGAGCAA-3’; GATA-1 forward primer 5’-
ACTGTGGAGCAACGGCTACT-3’ and reverse primer 5’-
TCCGCCAGAGTGTTGTAGTG-3’; and FOG-1 forward primer 5’- 
CATAGAGGAGCCCCCAAGTC-3’ and reverse primer 5’-
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GGCTGCCTCTTCTTCCTTTT-3’. The Power SYBR Green PCR master mix was from 
Applied Biosystems. The numbers of copies of β-catenin, GATA-1 and FOG-1 mRNA 
relative to 1,000 copies of β-actin mRNA reflect the abundance of mRNA copies detected. 
Drug treatment. Zileuton (Critical Therapeutics. Inc) and Imatinib (Novartis) were 
dissolved in water. The drugs were given orally in a volume of less than 0.3 ml by gavage 
(300 mg/kg, twice a day for Zileuton, and 100 mg/kg, twice a day for Imatinib) beginning 
at 8 days after bone marrow transplantation, and continuing until the morbidity or death 
of the leukemia mice. Water was used as placebo. 
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Supplementary Figure 1. Genes that are up-regulated by BCR-ABL in LSCs and 
not changed in expression following imatinib treatment. Bone marrow cells from 
C57BL/6 mice (B6) were transduced with retrovirus containing BCR-ABL/GFP or GFP 
alone to induce CML as described in Figure 1a. A group of these mice were treated with 
imatinib as described in Figure 1a. Bone marrow cells were isolated from the mice, and 
were sorted by FACS for GFP+Lin-c-Kit+Sca-1+ cells. Total RNA was isolated from these 
sorted cells for comparing Alox5 expression between GFP vector-transduced normal stem 
cells and BCR-ABL-transduced LSCs by DNA microarray.  
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Supplementary Figure 2. Loss of Alox5 causes failure of BCR-ABL-expressing BM 
cells to induce CML in secondary recipient mice. Kaplan-Meier survival curves for 
secondary recipients of 2x106 bone marrow cells from mice receiving BCR-ABL-
transduced wild type (n=5) or Alox5-/- (n=6) donor BM cells.  
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Supplementary Figure 3. Alox5-/- bone marrow cells do not have a homing defect. 
Bone marrow cells (6x106) from GFP mice (CD45.2) were 1:1 mixed with either bone 
marrow cells from wild type B6 mice (CD45.2) or those from Alox5-/- mice (CD45.2), 
and then transferred by tail vein injection into each wild type recipient mouse (CD45.1). 
3 or 6 hours after the transplantation, By FACS analysis, CD45.2+ bone marrow cells, 
representing the donor cells, were first identified and then analyzed for the percentages of 
GFP+ and GFP- populations. The ration of non-GFP and GFP populations were shown. 
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Supplementary Figure 4. Loss of Alox5 impairs the function of LSCs. BCR-ABL-
expressing wild type (CD45.1+) and Alox5-/- (CD45.2+) BM cells were 1:1 mixed (5x105 
each), followed by transplantation into lethally irradiated recipient mice. At 40 day after 
BMT, more than 80% of cells in PB were wild type (CD45.1+) leukaemia cells, and all 
these mice died of CML. 
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Supplementary Figure 5. Loss of Alox5 does not impair the function of normal stem 
cells. Alox5-/- (CD45.2) and wild type (CD45.1) BM cells were 1:1 mixed and then 
transferred into lethal recipient mice. 4 weeks after BMT, FACS analysis was carried out 
to compare the percentages of wild type and Alox5-/- cells in BM of the recipient mice. 
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Supplementary Figure 6. Alox5 deficiency does not lead to blockade of 
differentiation of normal LT-HSCs. Bone marrow cells were isolated from recipients of 
BCR-ABL-transduced bone marrow cells from wild type or Alox5-/-donor mice, and GFP- 
cell population (representing normal hematopoietic cells in CML mice) were analyzed by 
FACS analysis.  At 90 days after induction of CML, the percentages and total numbers of 
LT-HSCs (GFP-Lin-c-Kit+Sca-1+CD34-) were much lower than those of ST-HSCs /MPP 
cells (GFP-Lin-c-Kit+Sca-1+CD34+) in a similar degree in mice receiving either BCR-
ABL-transduced wild type or Alox5-/- donor bone marrow cells. These results indicate 
that Alox5 deficiency does not lead to blockade of differentiation of normal LT-HSCs. 
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Supplementary Figure 7. Analysis of apoptosis of LSCs in wild type and Alox5-/- 
mice. At day 14 after BMT, bone marrow cells were isolated from recipients of BCR-
ABL-transduced bone marrow cells from wild type or Alox5-/-donor mice. The cells were 
stained with PI and Hoechst Blue, and the percentages of LT-LSCs (GFP+Lin-c-Kit+Sca-
1+CD34-) and ST-LSCs /BCR-ABL-expressing MPP cells (Lin-c-Kit+Sca-1+CD34+) that 
were positive for PI and Hoechst Blue were determined by FACS. The ratios between 
ST-LSCs /BCR-ABL-expressing MPP cells and LT-LSCs in the presence and absence of 
Alox5 were compared. 
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Supplementary Figure 8. Comparison of white blood cell (WBC) counts. CML mice 
were treated with a placebo, Zileuton alone, imatinib alone, or both Zileuton and imatinib 
in combination as described in Figure 4b. WBCs were collected from the treated mice 14 
days after induction of CML. 
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Supplementary Figure 9. Inhibition of Alox5 prolongs survival of mice with CML 
induced with BCR-ABL-T315I. Kaplan-Meier survival curves for CML mice treated 
with a placebo (n=6), or Zileuton (n=11). 
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Supplementary Table. 1. Sequence of the primers used in real-time quantitative 
PCR assays. 
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Chapter IV 
A tumor suppressor role for the Msr1 gene in leukemia stem cells of chronic myeloid 
leukemia 
4.1 Abstract 
We have shown that Alox5 is a critical regulator of leukemia stem cells (LSCs) in a BCR-
ABL-induced chronic myeloid leukemia (CML) mouse model, and we hypothesize that 
the Alox5 pathway represents a major molecular network that regulates LSC function. 
Therefore, we sought to further dissect this pathway by comparing the gene expression 
profiles of wild type and Alox5-/- LSCs derived from our mouse model for BCR-ABL-
induced CML. DNA microarray analysis revealed a small group of candidate genes that 
exhibited changes in the levels of transcription in the absence of Alox5 expression.  In 
particular, we noted that the expression of the Msr1 gene was up-regulated in Alox5-/- 
LSCs, suggesting that Msr1 plays a tumor suppressor role in LSCs.  Using our CML 
mouse model, we show that Msr1 is down-regulated by BCR-ABL and this down-
regulation is partially restored by Alox5 deletion, and that Msr1 deletion causes 
acceleration of CML development. Moreover, Msr1 deletion markedly increases LSC 
function through its effects on cell cycle progression and apoptosis. We also show that 
Msr1 affects CML development by regulating the PI3K-AKT pathway and β-catenin. 
Together, these results demonstrate that Msr1 plays a tumor suppressor role in LSCs. The 
enhancement of Msr1 function may be of significance in the development of novel 
therapeutic strategies targeting CML. 
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4.2 Introduction 
         Cancer stem cells (CSCs) are believed to be promising targets with the potential to 
offer curative therapies for some types of cancer, especially leukemias. A number of 
genes and their pathways, including Wnt/β-catenin27,64, Hedgehog81, Notch156, Bim-1158, 
p53156, p16160 and p19170, Pten 161, PML 122, PP2A 133, Alox5 37, TGF-beta/FOXO 114 and 
Musashi 171, have been found to promote or inhibit CSC proliferation. Some of these 
genes and pathways also play similar roles in regulating the function of normal stem 
cells64,108,160.  There is a need to identify CSC-specific genes for developing anti-stem cell 
strategies. Chronic myeloid leukemia (CML) is a stem cell-derived hematologic 
malignancy and serves as a good disease for the study of CSC behavior and function. We 
have previously identified BCR-ABL-expressing Lin-Sca-1+c-Kit+ cells as leukemia stem 
cells (LSCs) in CML mice 26. We have demonstrated the critical role of the Alox5 gene in 
functional regulation of LSCs 37. We believe that the Alox5 pathway represents a major 
pathway that regulates the function of LSCs, and it will be important to identify other 
genes that interact with Alox5.  
In theory, genes regulating LSC function can be grouped in two categories:  those 
that enhance or promote LSC function or those that suppress and/or negatively regulate 
LSC function.  Genetic deletions and/or mutations in the latter group are likely to favor 
leukemogenesis and a few genes in this category have been identified in LSCs.  For 
example, Pten is down-regulated by BCR-ABL in LSCs. Pten deletion accelerates CML 
development and delays the disease upon over-expression 106. p53 is also down-regulated 
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by BCR-ABL and loss of p53 accelerates CML development 48,172. In this study, we 
identified that macrophage scavenger receptor (Msr1) functions as a tumor suppressor in 
BCR-ABL-expressing LSCs and CML development. Msr1 is a member of scavenger 
receptor family and is mostly expressed in hematopoietic cells 173. Msr1 is important for 
mediating host-cell interactions, macrophage adhesion and phagocytosis of apoptotic 
cells 115. Using Msr1-/- mice, we show that Msr1 delays CML development and regulates 
the self-renewal and differentiation capacity of LSCs through PI3K-AKT-GSK-3β and β-
catenin pathways. 
4.3 Results 
4.3.1 Loss of Msr1 accelerates CML development  
We previously demonstrated that Alox5 deficiency impairs the function of LSCs and 
prevents the initiation of BCR-ABL-induced CML. To identify the pathways in 
which Alox5 gene regulates function of LSCs, we performed a comparative DNA 
microarray analysis using total RNA isolated from non-BCR-ABL-expressing Lin-Sca-
1+c-Kit+, BCR-ABL-expressing wild type LSCs and BCR-ABL-expressing Alox5-/- LSCs. 
Our data identified Msr1 as a candidate gene important for LSC function, as it was down-
regulated by BCR-ABL and further restored by loss of Alox5 in LSCs (Figure 1a). This 
result was validated by quantitative real-time PCR analysis of non-BCR-ABL-expressing 
Lin-Sca-1+c-Kit+, BCR-ABL-expressing wild type LSCs and BCR-ABL-expressing Alox5-
/- LSCs (Figure 1b). To further demonstrate the regulation of Msr1 by BCR-ABL, we 
compared the cell surface expression levels of MSR1 between LSCs and HSCs by FACS 
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and found that MSR1 was down-regulated by BCR-ABL (Figure 1c).  This down-
regulation was rescued by the loss of Alox5 (Figure 1d). These results suggest that Msr1 
plays a tumor suppressor role in LSCs and CML development. To test whether Msr1 
affects CML development, we transduced bone marrow cells from 5-FU-treated wild type 
or Msr1-/- mice with BCR-ABL-GFP retrovirus and transplanted these cells into lethally-
irradiated recipient mice. Recipients of BCR-ABL-transduced bone marrow cells from 
Msr1-/- donor mice developed CML significantly faster than those receiving BCR-ABL-
transduced bone marrow cells from wild type donor mice (Figure 1e). The accelerated 
death of CML mice in the absence of Msr1 also correlated with an elevated percentage 
of GFP+Gr1+ myeloid leukemia cells and an elevated number of total leukemia cells in the 
bone marrow and spleens of recipient mice (Figure 1f). Accelerated CML development in 
the absence of Msr1 correlated with more severe infiltration of leukemia cells in the 
lung and spleen (Figure 1g and h). These results show a potent tumor suppressor role for 
Msr1 in BCR-ABL-induced CML.  
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Figure 1.  Msr1 deletion accelerates CML development 
 a. Expression of the Msr1 gene was up-regulated by Alox5 deletion in LSCs as compared 
to the sorted wild type GFP+Lin-c-Kit+Sca-1+ cells through DNA microarray. b. 
Expression of the Msr1 gene was significantly up-regulated by Alox5 deletion in LSCs 
when compared to wild type LSCs by RT-PCR. Mean value (±s.d.) for each group is 
shown (**: p<0.01). c. FACS analysis showed that MSR1 protein was down-regulated by 
BCR-ABL in LSCs when compared to GFP-Lin-c-Kit+Sca-1+ cells that did not express 
BCR-ABL. d. FACS analysis showed that MSR1 protein was up-regulated by Alox5 
deletion in CML stem cells when compared to wild type LSCs. e. Kaplan-Meier survival 
curves for recipients of BCR-ABL-transduced bone marrow cells from wild type or Msr1-
/- donor mice. All recipients of BCR-ABL-transduced bone marrow cells from Msr1-/- 
donor mice developed CML and died within 3 weeks of bone marrow transplantation 
(days post BMT), whereas recipients of BCR-ABL-transduced bone marrow cells from 
wild type donor mice survived longer. f. FACS analysis showed a higher percentage of 
GFP+Gr-1+ cells in the bone marrow and spleens of recipients of BCR-ABL-transduced 
bone marrow cells from Msr1-/- than wild type donor mice (**: p<0.01).Gross pathology 
of the lungs and spleens showed severe lung hemorrhages and splenomegaly in recipients 
of BCR-ABL-transduced bone marrow cells from Msr1-/- donor mice. g. Gross pathology 
and h. hematoxylin/eosin staining of the lungs and spleens showed severe lung 
hemorrhages and splenomegaly in recipients of BCR-ABL-transduced bone marrow cells 
from Msr1-/- donor mice. Recipient receiving pMSCV-GFP-transduced bone marrow cells 
was shown as a control. 
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4.3.2 Msr1 over-expression delays CML development 
To further test the tumor suppressor role of Msr1 in CML development, we co-
expressed BCR-ABL and Msr1 in wild type bone marrow cells by retroviral transduction 
and transplanted the transduced cells into recipient mice to induce CML. The BCR-ABL-
GFP expressing retrovirus was used as a control.  The BCR-ABL-IRES-Msr1-pMSCV 
construct expressed BCR-ABL and MSR1 in 293T cells (Figure 2a). We next transduced 
wild type donor bone marrow cells with BCR-ABL-Msr1 or BCR-ABL-GFP retrovirus and 
transplanted these cells into recipient mice. CML development was significantly slower in 
mice receiving bone marrow cells transduced with BCR-ABL-Msr1-GFP than in those 
receiving bone marrow cells transduced with BCR-ABL-GFP. Some recipient mice did 
not even develop the CML (Figure 2b). The delayed CML development correlated with 
fewer leukemia cells in peripheral blood (Figure 2c). In addition, FACS analysis of 
peripheral blood of recipients receiving BCR-ABL-Msr1 transduced bone marrow cells 
showed that the percentage of Gr-1+ myeloid leukemia cells declined with time (Figure 
2d). These results further support the role of Msr1 as a tumor suppressor in CML 
development. 
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Figure 2. Msr1 over-expression causes a delay of CML development 
 a. BCR-ABL and MSR1 were detected by protein blotting using antibodies against ABL 
and MSR1. MSR1 protein was detected in cells transfected with BCR-ABL-IRES-Msr1-
pMSCV. b.  Kaplan-Meier survival curves for recipients of BCR-ABL-IRES-pMSCV-
transduced bone marrow cells (n=7) or BCR-ABL-IRES-Msr1-pMSCV-transduced bone 
marrow cells (n=7) donor mice. FACS analysis showed that the total number c. and 
percentage d. of Gr-1+ cells in peripheral blood of recipients of BCR-ABL-IRES-pMSCV-
transduced bone marrow cells or BCR-ABL-IRES-Msr1-pMSCV-transduced bone marrow 
cells (*: p<0.05, **: p<0.01). 
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4.3.3 Msr1 deletion causes an increase in LSC function  
CML is a stem cell-derived disease and the accelerated development of CML in absence 
of Msr1 (Figure 1) prompted us to examine whether Msr1 regulates the function of LSCs. 
The accelerated CML development in the absence of Msr1 could be caused by an 
increase in the number of LSCs. To test this hypothesis, we quantified LSCs in the bone 
marrow and spleens of CML mice at 8, 10 and 14 days after CML induction. At day 
8, Msr1 deficiency did not cause an increase of LSCs in either bone marrow or spleen as 
compared to CML mice receiving BCR-ABL tranduced wild type bone marrow cells.  At 
day 14, a significant increase in Msr1-deficient bone marrow LSCs was observed (Figure 
3a), but Msr1 deficiency did not change the number of Msr1-/-LSCs in the spleen of CML 
mice (Figure 3a).  
The ability to transfer leukemia to next generation recipient mice can be used to examine 
the biological function of LSCs. We transduced wild type or Msr1-/- donor bone marrow 
cells with a lower titer BCR-ABL retrovirus and transferred the transduced cells to 
recipient mice to induce primary CML.  At day 13 after CML induction, bone marrow 
cells from primary CML mice were transplanted into secondary recipient 
mice.  Subsequently, leukemic bone marrow cells were serially transferred to recipient 
mice for two more generations. We found that BCR-ABL-expressing Msr1-/- bone marrow 
cells could transfer CML up to the fourth generation of recipient mice, while BCR-ABL-
expressing wild type bone marrow cells only transferred CML once in recipient mice 
(Figure 3b). These results suggest that Msr1 deficiency causes an increase in LSC 
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function. To further evaluate the effect of Msr1 on LSC function, we sorted wild type 
(CD45.1) and Msr1-/- (CD45.2) LSCs from bone marrow of CML mice by FACS. The 
sorted wild type and Msr1-/- LSCs were mixed in a 1:1 ratio (5000 LSCs for each group), 
and were transplanted into recipient mice. We observed that at day 10, the percentages of 
GFP+Gr-1+ wild type (CD45.1) and Msr1-/- (CD45.2) cells in peripheral blood of the mice 
were similar, and then gradually increased and eventually became a dominant leukemic 
cell population (Figure 3c). We also observed that Msr1 deficiency did not cause an 
increase in the homing ability of bone marrow cells (Supplementary Figure 1), which 
could result in accelerated CML development. To explain how the loss of Msr1 caused an 
increase in LSC function, we performed a DNA content analysis to examine the effect of 
Msr1 deficiency on cell cycle progression of LSCs. We found that the percentage of 
LSCs in the S+G2M phase was significantly higher in the Msr1-/- group than in the wild 
type group (Figure 3d), indicating that the loss of Msr1 causes more LSCs to enter the 
cell cycle, thereby enhancing the proliferation of LSCs. Furthermore, we examined 
whether Msr1 deletion reduces apoptosis of LSCs by staining the cells with 7AAD and 
Annexin V. We observed that apoptosis of Msr1-/- LSCs was reduced when compared 
with wild type LSCs (Figure 3e).  Thus, Msr1 regulates cell cycle progression and 
apoptosis of LSCs.  
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Figure 3. Msr1 deletion affects the function of LSCs 
a. Loss of Msr1 caused a significant increase in LSCs in bone marrow (*: p<0.05). Mean 
value (±s.d.) for each group is shown (*: p<0.05). b. Kaplan-Meier survival curves for a 
serial transplantation of  recipients of 1x106 bone marrow cells from mice receiving BCR-
ABL-transduced wild type (n=5) or Msr1-/- (n=5) donor bone marrow cells. c. Bone 
marrow cells derived from CML mice induced by transplanting BCR-ABL-transduced 
wild type (CD45.1) or Msr1-/- (CD45.2) donor bone marrow cells were isolated. 5×103 
wild type and Msr1-/- LSCs were sorted by FACS, mixed by 1:1 ratio, and transplanted 
into lethally irradiated secondary recipient mice. At days 10, 20, 25 and 30 after BMT, 
FACS analysis showed that the percentages of CD45.2+ cells were much higher than 
those of CD45.1+ cells. All these mice died of CML, presumably due to the development 
of CML from CD45.1+ cells. d. At 14 days post transplantation, bone marrow cells were 
isolated from recipients of BCR-ABL-transduced bone marrow cells from wild type 
or Msr1-/- donor mice. The cells were stained with Hoechst Blue, and the DNA content, 
represented by the percentages of LSC populations in the S+G2M phase of the cell cycle, 
was examined by FACS. Mean percentage for each cell population (n=4) is shown (*: 
p<0.05). e. At 14 days post transplantation, bone marrow cells were isolated from 
recipients of BCR-ABL-transduced bone marrow cells from wild type or Msr1-/- donor 
mice. The cells were stained with 7AAD and Annexin V, and the percentages of LSCs 
positive for 7AAD and Annexin V, representing apoptotic cells, were determined by 
FACS. 
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4.3.4 Induction of Msr1 expression by PMA causes inhibition of human CML cells 
and LSCs 
Next, we tested whether Msr1 inhibits human CML cells. Phorbol 12-myristate 13-
acetate (PMA) induces differentiation of THP-1 cells, leading to a marked increase in the 
expression of MSR1 on the cell surface 174. We found that the level of MSR1 was 
significantly increased in K562 cells treated with PMA for 48 hours (Figure 4a). We also 
noted that PMA significantly inhibited the proliferation of K562 cells (Figure 4b). The 
decreased proliferation of K562 cells was consistent with an increase in apoptosis (Figure 
4c). We also tested whether PMA inhibits LSCs from CML in vitro under stem cell 
culture conditions. We cultured bone marrow cells from CML mice in the presence of 
imatinib (1 µM) or PMA (80 nM) for 3 days, and calculated the total number and 
percentage of LSCs that remained at the end of the culture based on FACS analysis and 
total cell counts (Figure 4d). We showed that PMA significantly inhibited LSCs in vitro. 
To further confirm that PMA treatment promotes LSC killing through induction of Msr1, 
we treated bone marrow cells from recipients receiving BCR-ABL-transduced bone 
marrow cells from Msr1-/- donor mice with PMA (80 nM) for 3 days and calculated the 
total number and percentage of LSCs that remained at the end of the culture based on 
FACS analysis and total cell counts. The percentage of Msr1-/-LSCs wasn’t reduced by 
PMA treatment although the total number of Msr1-/-LSCs was reduced about 35% by 
drug treatment, which is still much lower than WT LSCs treated by PMA (Figure 4e).   
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Figure 4. PMA inhibits proliferation and induces apoptosis of human CML cells 
a. FACS analysis showed that MSR1 protein was up-regulated in K562 cells treated with 
PMA for 48 h compared to untreated cells. b. PMA inhibits proliferation of K562 cells. 
K562 cells were treated with DMSO or PMA (80 nM) for 48 and 96 hours, and live cells 
were counted (**: p<0.01). c. PMA induces apoptosis of K562 cells. K562 cells were 
treated with DMSO or PMA (80 nM) for 48 hours. Apoptotic cells (Annexin V+/7AAD+) 
cells were analyzed by FACS (**: p<0.01). d. PMA inhibits LSCs from CML mice in 
vitro. Bone marrow cells isolated from mice with CML induced by BCR-ABL-GFP were 
cultured (2×106 cells/6cm plate) under stem cell conditions (see Methods) in the presence 
of DMSO, imatinib (1 µM)or PMA(80 nM) for 3 days, followed by FACS analysis of 
LSCs (*: p<0.05, **: p<0.01). e. Msr1-/- LSCs were treated by PMA in a stem cell culture 
condition. Bone marrow cells from recipients receiving BCR-ABL-transduced bone 
marrow cells from Msr1-/- donor mice were treated with PMA (80nM) for 3 days. The 
total number and percentage of LSCs that remained at the end of the culture were 
calculated by FACS analysis and total cell counts. The percentage of Msr1-/-LSCs wasn’t 
reduced by PMA treatment although the total number of Msr1-/-LSCs was reduced about 
35% by drug treatment, which is still much lower than WT LSCs treated by PMA.  
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Figure 4. PMA inhibits proliferation and induces apoptosis of human CML 
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cells4.3.5 Msr1 deletion does not affect the function of normal HSCs 
We further tested whether the loss of Msr1 affects the function of normal HSCs. We first 
compared hematopoietic cell lineages in bone marrow and peripheral blood of Msr1-/-
mice with those of wild type mice. The percentages of HSCs (Lin-c-Kit+Sca-1+), LT-
HSCs (Lin-c-Kit+Sca-1+CD34-), ST-HSCs (Lin-c-Kit+Sca-1+CD34+Flt3-) and MPPs (Lin-
c-Kit+Sca-1+CD34+Flt3+) in bone marrow of Msr1-/-mice were only slightly higher than 
those of wild type mice (Figure 5a), and the percentages of Gr-1+, Mac-1+, B220+ or 
CD3E+ cell populations in bone marrow were similar between wild type and Msr1-/- mice 
(Figure 5b). To compare the function of HSCs between Msr1-/- and wild type mice, we 
conducted an irradiation rescue assay, in which several doses of Msr1-/- or wild type bone 
marrow cells were transplanted into lethally-irradiated wild type mice. Survival of mice 
receiving wild type or Msr1-/- bone marrow cells was similar (Figure 5c). To more 
stringently compare the stem cell function, we carried out a competitive reconstitution 
analysis, in which wild type (CD45.1) and Msr1-/- (CD45.2) bone marrow cells were 
mixed in a 1:1 ratio and then transferred into recipient mice by tail vein or bone injection. 
Twelve weeks after the transplantation, the percentages of wild type (CD45.1) and Msr1-
/- (CD45.2) were similar in peripheral blood of the mice (Figure 5d), indicating that Msr1 
did not suppress the function of normal HSCs. 
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Figure 5. Msr1 deletion does not affect the function of normal HSCs 
a.  Bone marrow cells from wild type and Msr1-/- mice were analyzed by FACS for the 
percentages of total HSCs (Lin-c-Kit+Sca-1+), LT-HSCs (Lin-c-Kit+Sca-1+CD34-), ST-
HSCs (Lin-c-Kit+Sca-1+CD34+Flt3-) and MPPs (Lin-c-Kit+Sca-1+CD34+Flt3+). b. Cells 
from bone marrow and peripheral blood of wild type and Msr1-/- mice were analyzed by 
FACS for the percentages of Gr-1+, B220+ and CD3E+cells. c. Three doses (1×105, 
5×104 and 2.5×104) of wild type or Msr1-/- bone marrow cells were injected into lethally-
irradiated recipient mice. Survival curves showed that there was only a minor 
engraftment defect of bone marrow cells in Msr1-/- mice. d. Msr1-/- (CD45.2) and wild 
type (CD45.1) bone marrow cells were 1:1 mixed and then transferred into recipient mice 
(n=5). 12 weeks after transplantation, FACS analysis showed the percentages of wild 
type and Msr1-/- cells in peripheral blood of recipient mice. 
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Figure 5. Msr1 deletion does not affect the function of normal HSCs 
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4.3.6 Msr1 affects CML development by regulating the PI3K-AKT-GSK-3β and β-
catenin pathways 
To determine the signaling pathways involved in Msr1 function, we analyzed protein 
lysates isolated from the spleens of CML mice receiving BCR-ABL-transduced wild type 
or Msr1-/- donor bone marrow cells. Loss of Msr1 resulted in a marked activation of the 
PI3K-AKT-GSK3β pathway and increased expression of β-Catenin (Figure 6a). 
Conversely, we tested whether the up-regulation of Msr1 expression inhibits these 
signaling molecules by treating K562 cells with PMA. PMA markedly inhibited the 
activation of the PI3K-AKT and reduced expression of β-Catenin (Figure 6b). To confirm 
whether over-expression of Msr1 inhibits those signal pathways in BCR-ABL expressing 
leukemic cells, we over-expressed Msr1 gene in human leukemic cells. We made the 
pMSCV-Msr1-GFP construct and pMSCV-GFP retrovirus was used as a control 
(Supplementary Figure 2a). The pMSCV-Msr1-GFP construct expressed MSR1 and GFP 
while the pMSCV-GFP construct only expressed GFP in 293T cells (Supplementary 
Figure 2b). We next transduced human leukemia cells with pMSCV-Msr1-GFP or 
pMSCV-GFP retrovirus, sorted GFP+K562 cells out and further confirmed over-
expression of MSR1 in K562 cells by FACS and Western blot (Supplementary Figure 2c 
and Figure 6d). The over-expression of Msr1 inhibited the activation of the PI3K-AKT, 
reduced expression of β-Catenin (Figure 6d) and further suppressed proliferation of 
leukemia cells (Figure 6e). Together, these results suggest that Msr1 is a negative 
regulator between BCR-ABL-activated Alox5 and the PI3K-AKT-GSK-3β and β-Catenin 
pathways (Figure 6f). 
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Figure 6. Msr1 affects CML development by regulating PI3K-AKT-GSK-3β 
pathway and β-Catenin 
a. Msr1 regulates signaling pathways involved in the regulation of LSC functions. 
Spleens of recipients of BCR-ABL-transduced wild type or Msr1-/- donor bone marrow 
cells (n=4) at 14 days after transplantation were collected and protein lysates were 
prepared for expression of a group of signaling molecules. Loss of Msr1 markedly 
activated the PI3K-AKT pathway and increased expression of β-Catenin. b. 
Quantification of relative protein expression levels in spleens of recipients of BCR-ABL-
transduced wild type or Msr1-/- donor bone marrow cells. Mean value (±s.d.) for each 
group (n=4) is shown (*: p<0.05, **: p<0.01).  c. PMA inhibits PI3K-AKT signaling 
pathways and β-Catenin expression in human CML cells. K562 cells were treated with 
PMA, and protein lysates were collected for expression of a group of signaling molecules. 
PMA markedly inhibits activity of PI3K-AKTand reduced expression of β-Catenin. d. 
Over-expression of Msr1 gene inhibits PI3K-AKT signaling pathways and slightly 
reduces β-Catenin expression in human CML cells. K562 transduced with pMSCV-Msr1-
GFP or pMSCV-GFP retrovirus were cultured and protein lysates were collected for 
expression of a group of signaling molecules. Over-expression of Msr1 gene markedly 
inhibits activity of PI3K-AKTand reduced expression of β-Catenin. e. Msr1 suppresses 
the proliferation of human leukemic cells. The same number of K562 cells transduced 
with pMSCV-GFP or pMSCV-Msr1-GFP was cultured in 24 wells plate. The live cells 
were counted at 24h, 48h and 96h (*: p<0.05, **: p<0.01).  f. A summary of Msr1 
pathway in LSCs of CML. 
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Figure 6.    Msr1 affects CML development by regulating PI3K-AKT-GSK-3β 
pathway and β-catenin 
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4.3.7 Msr1 does not affect BCR-ABL-induced lymphoid leukemia 
We also tested whether Msr1 affects BCR-ABL-induced acute lymphoblastic leukemia 
(ALL), which originates from committed lymphoid progenitors. Wild type or Msr1-/-
 donor bone marrow cells were transduced by BCR-ABL-GFP retrovirus, followed by 
transplantation cells into lethally irradiated wild type recipient mice. Both groups of mice 
developed and died of ALL with similar disease latency and survival time (Figure 7a). 
FACS analysis of lymphoid leukemia cells showed that both groups of ALL mice had 
similar percentages of B220+ leukemia cells in peripheral blood of these mice (Figure 7b 
and c) although the mass of spleen in Msr1-/- donor group was slightly more elevated than 
wild type group (Figure 7d). Together, these results showed that Msr1 did not affect the 
development of BCR-ABL induced ALL, and suggest that Msr1 is not required by ALL 
stem cells, but is required by CML stem cells.  
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Figure 7. Msr1 does not affect BCR-ABL-induced lymphoid leukemia 
a. Kaplan-Meier survival curves for recipients of BCR-ABL-transduced bone marrow 
cells from wild type (n=10) or Msr1-/- (n=8) donor mice. Both groups of mice developed 
and died of ALL. b and c FACS analysis showed similar numbers of GFP+B220+ cells in 
peripheral blood of recipients of BCR-ABL-transduced bone marrow cells from wild type 
(n=5) or Msr1-/- (n=5) donor mice. d. Spleen masses of recipients of BCR-ABL-
transduced bone marrow cells from Msr1-/-(n=9) donor mice is similar to wild type 
(n=4) donor mice.  
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Figure 7. Msr1 does not affect BCR-ABL-induced lymphoid leukemia 
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4.4 Discussion 
In this study, we show that the reduction of LSCs in the absence of Alox5 is 
partially due to an up-regulated expression of Msr1 since Msr1 inhibits the proliferation 
of LSCs. Our finding suggest that both Msr1 and Alox5 are in the same pathway and that 
Msr1 functions downstream of Alox5 as a tumor suppressor gene in BCR-ABL-induced 
CML. Compared to well studied tumor suppressor genes like Pten and p53, Msr1 may 
represent a new group of genes with tumor suppressive activities, because deletion of this 
gene in mice does not result in tumor development (data not shown). Genetic changes to 
Msr1 have been shown to be related to prostate cancer risk, although the underlying 
mechanism is unclear118 . Our data demonstrate that the expression of Msr1 is down-
regulated by BCR-ABL. Loss of Msr1 function leads to accelerated development of CML 
in mice, and this disease phenotype can be rescued by ectopic Msr1 expression. Together, 
the results in this study reveal the functional relationship between Msr1 and Alox5, i.e. 
BCR-ABL activates Alox5 in LSCs, leading to reduced expression of Msr1. Thus, 
restoration of Msr1 expression provides a strategy for shutting down the Alox5 pathway 
required for LSC function 37. Thus, the impetus for the identification of genes critical to 
LSC function in CML is the opportunity to find pathways that may be targeted for 
eradicating CML LSCs. Remarkably; enhanced Msr1 expression may provide a means 
for eliminating LSCs and preventing CML. Our findings that the pharmacological 
induction of Msr1 impairs BCR-ABL expressing LSCs, as well as human CML cells, lend 
credence to the notion that Msr1 agonists may be used as a novel therapeutic strategy for 
eradicating LSCs in CML. Targeting Alox5 and Msr1 in combination with the BCR-ABL 
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kinase inhibitor imatinib or a BCR-ABL protein inhibitor, such as an HSP90 inhibitor, 
may provide a novel approach that leads to better clinical control of CML and the 
depletion of LSCs.   
Our results also provide insight into the cellular mechanism for CML 
development in the absence of Msr1. The CML serial transplantation assay and LSC 
competition assay suggest that the accelerated CML development is caused by the 
significantly enhanced ability of LSCs to self-renew and induce leukemia in the absence 
of Msr1. The enhanced function of LSCs in the absence of Msr1 is due to an increase in 
the number of LSCs in S+G2M phase and a decrease in LSC apoptosis. However, Msr1 
deficiency does not appear to significantly affect normal HSCs, which is consistent with 
our observation that Alox5 deletion only affects LSCs instead of normal HSCs83 37.  
The molecular mechanism for the functional regulation of LSCs by Msr1 remains 
largely unknown.  We show that the loss of Msr1 function leads to activation of the 
PI3K-AKT pathway and up-regulated expression of β-catenin. By contrast, up-regulation 
of Msr1 by PMA inhibits the activity of the PI3K-AKT pathway and reduces the 
expression of β-catenin.  We and others have recently shown that β-catenin plays a 
critical role in CML LSCs 27,64, and that Akt affects the progression of BCR-ABL-induced 
leukemia in a mouse model 106. Thus, the regulation of these LSC-related genes by Msr1 
indicates its potential role in the development of BCR-ABL-induced CML. Because Alox5 
regulates expression of β-catenin in LSCs37and loss of Alox5 up-regulatesthe expression 
148 
 
of Msr1, we propose that Alox5 and Msr1 are functionally linked and critical for LSC 
function.  More studies are needed to explain how Msr1 suppresses LSCs in CML.  
4.5 Materials and methods 
Mice 
C57BL/6, B6.SJL-Ptprca Pepcb/BoyJ, homozygous Alox5 knockout (Alox5-/-) mice and 
homozygous Msr1 knockout (Msr1-/-) mice in a C57BL/6 background were obtained 
from The Jackson Laboratory (Bar Harbor, Maine). Mice were maintained in a 
temperature- and humidity-controlled environment and given unrestricted access to 6% 
chow diet and acidified water.  
Microarray 
To perform the microarray to compare the gene profiles, we used the bone marrow 
transplantation mouse model of CML as an assay system, in which bone marrow cells 
from donor mice pre-treated with 5-fluorouracil (5-FU) and transduced with BCR-ABL 
result in development of CML in recipient mice. We transduced bone marrow cells from 
C57BL/6 (B6) mice or Alox5-/- mice with retrovirus containing BCR-ABL/GFP or GFP 
alone under conditions for induction of CML, followed by transplantation of the 
transduced cells into B6 recipient mice (30 recipient mice for each group). 14 days after 
BMT, bone marrow cells were isolated and subsequently sorted by FACS for LSCs 
(GFP+Lin-c-Kit+Sca-1+). Total RNA was isolated from these BCR-ABL-expressing LSCs 
or from the GFP+Lin-c-Kit+Sca-1+ cells that only expressed GFP, and DNA microarray 
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analysis was carried out to compare gene expression among the different groups by using 
Affymetrix Chips. 
 Construct  
Human Msr1 cDNA are kindly provided by Dr.Sulahian (Harvard School of Public 
Health). To make the MSCV-BCR-ABL-Msr1 construct, Msr1 cDNA was amplified by 
Msr1-EcorI 5’GAATTCATGGAGCAGTGGGATCACTTTC3’ and Msr1-ClaI 
5’ATCGATTTATAAAGTGCAAGTGAC3’.  The cDNA was sequenced from both ends 
to confirm the sequence. The Msr1 cDNA was cloned into the pMSCV-BCR-ABL-GFP 
vector between MfeI and ClaI sites.  
To make the pMSCV-Msr1-GFP construct, Msr1 cDNA was amplified by Msr1-EcorI 
5’GAATTCATGGAGCAGTGGGATCACTTTC3’ and Msr1-ClaI 
5’ATCGATTTATAAAGTGCAAGTGAC3’.  The cDNA was sequenced from both ends 
to confirm the sequence. The Msr1 cDNA was cloned into the pMSCV -GFP vector at the 
EcorI site. 
Cell lines 
Human K562 myeloid leukemia cell line was grown in RPMI 1640 medium containing 
10% FCS. To generate the Msr1-expressing K562 cell lines, K562 cells were 
transduced with the pMSCV-Msr1-GFP retrovirus, followed the Msr1-expressing cells 
were selected by GFP sorting by fluorescence-activated cell sorter (FACS). K562 cells 
transduced with the pMSCV-GFP retrovirus were used as a control. The livable cells 
were counted by Trypan Blue staining. 
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Flow cytometry and identification of leukemia and normal hematopoietic cell 
lineages. 
Hematopoietic cells were collected from the bone marrow and peripheral blood of the 
normal and diseased mice.  Erythrocytes were lysed in NH4Cl red blood cell lysis buffer 
(pH 7.4). The cells were washed with PBS and stained with B220-PE for B cells, Gr-1-
APC for neutrophils, Mac-1-PE for macrophages, CD3E-APC for T cells and Sca-1/c-
Kit/CD34/CD135 (Flt3)/CD204 for HSCs. All of these antibodies were purchased from 
Ebioscience Inc and Serotec Inc.  After staining, the cells were washed once with PBS 
and subjected to FACS analysis. 
Bone marrow transduction/transplantation 
The retroviral vector MSCV-IRES-GFP carrying the p210 BCR-ABL cDNA and retroviral 
transduction/transplantation of mouse bone marrow cells for induction of CML and ALL 
by BCR-ABL have been described previously36,149. 
Western blot analysis and antibodies 
Antibodies against c-ABL, β-actin, β-catenin and MSR1 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA) and antibodies against p-Pten, Pten, p-PI3K, PI3K, p-
AKT, AKT, p-GSK-3β and GSK-3β from Cell Signal Technology (Danvers, MA). 
Protein lysates were prepared by lysing cells in RIPA buffer and western blotting was 
carried out as described previously 4. 
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In vitro culture of LSCs and drug treatment 
Bone marrow cells isolated from CML mice were cultured in vitro in the presence of 
Stemspan SFEM (Stemcell Technologies, Vancouver, CA), stem cell factor, insulin-
like growth factor-2, thrombopoietin, heparin, and α-fibroblast growth factor as described 
previously 125. PMA (Sigma) were dissolved in dimethyl sulfoxide (DMSO) to make 
stock solution at 10mM, and were then diluted in culture media to different 
concentrations for use. 
Histology 
The lungs from the placebo- or drug-treated mice were fixed in Bouin fixative (Fisher 
Scientific, Pittsburgh, PA) for 24 hours at room temperature, followed by an overnight 
rinse in water. Ten-µm sections were stained with hematoxylin and eosin (H&E) and 
observed by a model DMRE compound microscope (Leica, Heidelberg, Germany). All 
sections were imaged with a 2.5 x PH1 objective (NPLan, NA 0.25) and 10 x PH1 
objective (NPLan, NA 0.40). All images were imported into MetaMorph software 
(Molecular Devices, Downingtown, PA) as a series of tagged image files. All images 
were then constructed in Adobe Photoshop 7.0 (Adobe, San Jose, CA).  
Statistics  
Statistical analyses were performed by using Student t Test (*: p<0.05, **: p<0.01) 
(GraphPad Prism v5.01 software for Windows, GraphPad Software, San Diego, CA 
USA). 
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Supplementary Figure 1. Msr1-/- bone marrow cells do not exhibit a homing defect 
Bone marrow cells (6x106) from GFP mice (CD45.2) were mixed 1:1 with either bone 
marrow cells from wild type mice (CD45.2) or those from Msr1-/- mice (CD45.2) and 
then transplanted by tail vein injection into wild type recipient mice (CD45.1). Three 
hours after the transplantation, by FACS analysis, CD45.2+ bone marrow cells, 
representing the donor cells, were first identified and then analyzed for the percentages of 
GFP+ and GFP- populations. The ratio of non-GFP and GFP populations were shown. 
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Supplementary Figure 2. Msr1 is over-expressed in human leukemic cells.  
a. pMSCV-Msr1-GFP construct was made and pMSCV-GFP retrovirus was used as a 
control.  b. pMSCV-Msr1-GFP construct expressed MSR1 and GFP together while 
the pMSCV-GFP construct only expressed GFP in 293T cells. c. Human leukemic cells 
were tranduced with pMSCV-Msr1-GFP or pMSCV-GFP retrovirus. GFP+K562 cells 
were sorted out and the expression of MSR1 was measured by FACS. 
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Final Summary and Discussion 
The work described in this chapter has been published (Chen Y, Li D, Li S. The Alox5 
gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell 
Cycle. 2009, 8(21): 3488-3492.) 
 
In my Ph.D thesis, I focus on looking for the new target on leukemia stem cells of 
CML. First, we evaluated the effects of Omacetaxine on BCR-ABL-induced chronic 
myeloid leukemia and acute lymphoblastic leukemia in mice. Second, we used our CML 
mouse model and compared the global gene profile between normal HSCs and LSCs to 
identify the up-regulation of Alox5 in CML LSCs. Finally, we sought to further dissect 
this pathway by comparing the gene expression profiles of wild type and Alox5-/- LSCs 
derived from our mouse model for BCR-ABL-induced CML. In particular, we identified 
that Msr1 plays a tumor suppressor role in LSCs. 
Our strategy for targeting LSCs  
 A straightforward strategy for targeting LSCs is through inhibiting development-
related genes that play roles in regulation of both normal HSCs and LSCs, as many of 
these genes have been identified and initially found to play critical roles in the 
development of normal HSCs. However, a potential problem of this strategy is that 
normal stem cells could be simultaneously inhibited during a long-term cancer treatment, 
leading to severe side effects potentially.  One strategy for inhibiting LSCs is to target 
genes that play crucial roles in functional regulation of LSCs but not normal HSCs, and 
obviously, the challenge for taking this approach is to first identify these key stem cell-
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specific genes, as expression of many genes can be altered by an oncogene including 
BCR-ABL in CML and not all these genes are essential for survival and self-renewal of 
LSCs. The Alox5 gene is probably the first LSC-specific gene identified and shown to 
play a critical role in LSCs but not normal HSCs, and our identification of this gene in 
LSCs shows a good example for how we design a strategy for targeting LSCs. In our 
study, the Alox5 gene was picked for further functional study based on our comparison of 
gene expression profiles between normal HSCs and LSCs by DNA microarray analysis, 
in which Alox5 is shown to be up-regulated by BCR-ABL, which was confirmed by real-
time PCR analysis. Alox5 has been shown to be associated with many important signaling 
pathways including P53 and PI3K, and is thought to be involved in many different types 
of diseases87,161. We believe that the Alox5 pathway represents a major molecular 
network that regulates the function of LSCs, and much more work needs to be done to 
fully dissect this pathway.  
Recently, Alox5 was identified as a novel target in glioma stem-like cells (GSLCs) 
and its inhibition with Nordy exhibits therapeutic implications through inducing GSLC 
differentiation. Alox5 gene was shown to have a heterogeneous expression pattern in 
human glioblastoma cells and its preferential expression in a GSLC population. The 
synthetic Alox5 inhibitor (Nordy) was reported to inhibit self-renewal and induced 
differentiation of GSLCs in vitro and in vivo. The Alox5 inhibitor was found to attenuate 
the growth of GSLCs in vitro and reduced the GSLC pool through a decrease in the 
CD133 (+) population and abrogated clonogenicity. The Alox5 inhibitor appeared to 
exert its effect via astrocytic differentiation by up-regulation of GFAP and down-
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regulation of stemness related genes, rather than by inducing apoptosis of GSLCs. The 
growth inhibition of xenografted glioma by Nordy was more long-lasting compared with 
that of the akylating agent BCNU, which exhibited significant relapse on drug 
discontinuation resulting from an enrichment of GSLCs. And transient exposure to Nordy 
reduced tumorigenecity of GSLCs and induced differentiation of the xenografts175. 
Targeting of cancer stem cells (CSCs) have become an important issue in 
developing new therapies of cancer. As described above, we believe that the key to 
eradicating CSCs is to identify critical pathways responsible for regulating self-renewal 
and differentiation of CSCs but not normal stem cells. The Alox5 study in leukemia stem 
cells and glioma stem-like cells has shown that this strategy is feasible. Using CML 
induced by BCR-ABL as a model disease, here we propose a strategy for identifying new 
therapeutic targets in CSCs (Figure 1).  Isolation of LSCs and normal HSCs is a key 
initial step to obtaining high-quality RNA for microarray analysis. In our study, BCR-
ABL-expressing HSCs (GFP+Lin-c-Kit+Sca-1+) represent LSCs in CML mice. It is 
important to realize that the microarray analysis will show many genes that were up- and 
down-regulated by BCR-ABL in LSCs, and the key is to select candidate genes for further 
functional tests. Prior to the functional tests, we always confirm expression change of a 
gene of interest by real-time PCR. The function of a candidate gene can be primarily 
determined based on the literature or database search. The last step is to functionally test 
a candidate gene using knockout or transgenic strains.  
Future directions 
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Imatinib effectively inhibits BCR-ABL kinase activity, but does not remove 
BCR-ABL protein, which may partially explain why imatinib does not eradicate LSCs in 
CML. In fact, we have shown that total number and percentage of LSCs in bone marrow 
of CML mice gradually increase with time during imatinib treatment, although the BCR-
ABL kinase activity is greatly inhibited by imatinib. These results indicate that inhibition 
of BCR-ABL kinase activity alone is insufficient to completely shut down BCR-ABL, 
and that other strategies need to be developed. Our demonstration of the role of Alox5 in 
regulating the function of LSCs but not normal HSCs identifies the first LSC-specific 
gene in CML, and provides us with an exciting opportunity to explore the regulatory 
molecular pathways in LSCs. In our Alox5 study, we have primarily linked the Alox5 
pathway to activation of β-catenin and a cell surface receptor Msr1, as we showed that 
loss of Alox5 caused down-regulation of β-catenin expression and up-regulation of Msr1 
in LSCs, but not in normal HSCs. Several important questions remain to be answered:  
1) How does Alox5 regulate the development of cancer stem cells? Recently, the 
Alox5 gene was reported to be essential for self-renewal and differentiation of glioma 
stem cells175. It has also been shown that the Alox5 pathway is utilized early during the 
differentiation of embryonic stem cells into cells of a myeloid lineage176.  These findings 
suggest a unique role for the Alox5 gene in the development of both normal stem cells 
and cancer stem cells. Our BCR-ABL mouse model is a good tool to study the 
mechanism of Alox5 in cancer stem cells. To investigate how Alox5 gene is activated in 
LSCs, Alox5 promoter studies will be initiated to analyze its transcriptional regulation.  
The key genes regulating self-renewal and differentiation of stem cells like OCT4, SOX-
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2 and CD133 will also be tested in LSCs with or without Alox5 gene. The mechanism by 
which Alox5 regulates these stem cell -specific genes will also be investigated. This 
study will help us to establish the potential link among BCR-ABL, Alox5 gene and cancer 
stem cells and identify new targets for inhibiting the LSCs of CML.  
2) What is the function of other genes of the Alox5 pathway in LSCs? Our results 
indicate that Alox5, a gene critical to the production of leukotrienes in the arachidonic 
acid metabolism pathway, is required for CML development, likely through its effect on 
CML stem cell maintenance. Next, it is important to understand the function of other 
genes of arachidonic acid metabolism like Alox12/15 and PEG2 in LSCs and CML 
development. It is also necessary to understand the function of leukotrienes and other 
leukotriene related genes in LSCs. For example, leukotriene B4 (LTB4) is produced by 5-
LO and exported from the cell by specific transporter proteins. LTB4 acts by binding to 
the B leukotriene receptor 1 (Blt1), which is located on the outer plasma membrane of 
structural and inflammatory cells. To characterize the function of LTB4 in LSCs, LSCs 
will be treated with LTB4 and the proliferation of LSCs will be measured. The function 
of LTB4 receptor Blt1 in LSCs will also be examined using Blt1 knockout mouse. LTA4 
hydrolase (Lta4h) is another key gene in leukotriene metabolism, which converting 
leukotriene A4 (LTA4) the product of Alox5 to leukotriene B4 (LTB4). The function of 
LTA4 and Lta4h in LSCs is not clear. The function of Lta4h in LSCs may be examined 
using Lta4h knockout mice.  
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  3) How does BCR-ABL inhibit Msr1 expression and how does Msr1 regulate 
PI3K-AKT pathway? Msr1 is a cell surface receptor expressing on HSCs and is down-
regulated by BCR-ABL. Msr1 suppresses the CML development and enhances the 
function of LSCs. It is still not clear that how BCR-ABL inhibits Msr1 expression, what 
signaling pathway or transcription factors link the BCR-ABL and Msr1, and how those 
signaling pathways are changed by the loss of Alox5 gene. Over-expression of Msr1 
inhibits PI3K and AKT pathway in human leukemia cells. The mechanism of Msr1 
inhibiting PI3K and AKT kinases activity is still unknown.  For example, will Msr1 
activate or inactivate any potential phosphorylation, ubiquitination, acetylation, 
methylation and other post-translational modification sites of PI3K and AKT? Will Msr1 
also activate or inactivate other signaling pathways? Mass spectrometry analysis of PI3K 
and AKT post-translational modification from cells with or without over-expressed of 
Msr1 will help to identify any potential phosphorylation, ubiquitination, acetylation, 
methylation and other post-translational modification sites of PI3K and AKT. Microarray 
or RNA-Seq analysis will be help to find out whether Msr1 activates or in activates other 
signaling pathways.  
We believe that all these studies will help us to understand the mechanism of self-
renewal or differentiation of cancer stem cells and find a new strategy to effectively 
target cancer stem cells for developing curative therapies. 
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Figure 1. Our strategy for identification of genes that play key roles in regulating the 
functions of LSCs. One of the most critical steps in this approach is to analyze DNA 
microarray data to provide a short list of candidate genes. 
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